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Lactate is both a metabolite of glycolysis, and a component of several signaling pathways.
Although recent studies indicate that lactate is a critical regulator of cancer development, very
little is known about lactate metabolism in the context of metastatic cancer. Epithelial-to
mesenchymal transition (EMT) promotes metastasis by inducing invasive properties in epithelial
tumors. To determine whether EMT induces metabolic alterations, we have studied two epithelial
breast cancer cell lines (MCF-7 and BT-474) and their respective EMT-induced mesenchymal
progeny (MCF-7 M and BT-474 M) for changes in lactate metabolism. Metabolic analysis
revealed that EMT induced an enhanced glycolytic profile in mesenchymal breast cancer cells
along with the overexpression of glucose transporters (GLUT3, GLUT12), lactate dehydrogenases
(LDHA, LDHB) and monocarboxylate transporter 4 (MCT4). In contrast, epithelial breast cancer
cells preferentially use oxidative phosphorylation (OXPHOS) to produce ATP. These aerobic
epithelial breast cancer cells expressed the monocarboxylate transporter 1 (MCT1) and maintained
significantly higher intracellular levels of lactate and pyruvate. The strong expression of the lactate
importer MCT1 in epithelial breast cancer cells may involve the ERα-inducible GATA3
transcription factor. GATA3 is central to normal breast development, and is expressed in ERα
positive breast cancer. Using the UCSC Genome Browser, we detected a specific GATA3 binding

Denisse Guadalupe Tafur-Cotrina, Ph.D. - University of Connecticut, 2017
site in the DNAse-hypersensitive region within the promoter of MCT1 gene, and found that
knockdown of GATA3 represses MCT1 expression. We also observed that the endogenous lactate
receptor, G-protein coupled receptor 81 (GPR81), was highly expressed in epithelial breast cancer
cell lines and hormone-positive breast cancer tumors but was suppressed in post-EMT
mesenchymal cancer cells or triple negative breast cancer (TNBC) tumors. GPR81 regulated
MCT1 expression and lactate uptake in epithelial breast cancer cells and its expression was crucial
for cell proliferation and survival under nutrient limited conditions. This study provides an
overview of specific metabolic changes induced by EMT in two independent and substantially
different epithelial breast cancer cell lines. In addition, we propose GPR81 as a potential
prognostic marker and therapeutic target in hormone positive epithelial breast cancer.
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CHAPTER 1

GENERAL INTRODUCTION
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I.

THE BREAST
i.

Anatomy

The female breast represents a gland that is specialized in the synthesis, secretion and delivery of
milk to the newborn. This complex tissue is composed of lobules (milk producing glands), ducts
(milk-carrying tubes), blood vessels, lymph nodes and stroma (adipose and connective tissue
surrounding the ducts and lobes). The breast is organized into 15 to 20 lobes, each lobe has 20 to
40 lobules which consist of clusters of alveoli containing mammary secretory epithelial cells.
Lobules are connected to very small ducts that merge into a unique duct for each lobe (2-4.5 cm
long) that ends in its own opening at the nipple. The dark area of skin surrounding the nipple that
contains sweat and sebaceous glands is called the areola. Although the breast is mature after puberty,
the breast tissue remains inactive until pregnancy1,2.
ii.

Development

The breast undergoes many changes in structure and function during a woman’s lifetime in
response to hormonal stimuli1. From birth through childhood, the mammary gland remains small
and immature3. Later during puberty, hormones produced by the ovaries and pituitary gland cause
the breast to grow and mature. This maturation process is called branching morphogenesis and
involves enlargement of the milk ducts by expansion of the epithelial ductal cells4. During
pregnancy, prolactin and placental lactogen induce the alveolar epithelial cells to proliferate and
differentiate into milk-secreting cells. During lactation, milk is secreted by epithelial cells and
accumulated in the lumen of the alveoli. Oxytocin, stimulated by suckling infant, causes the
contraction of the surrounding myoepithelial cells that moves the milk through the ductal tree and
to the nipple. Upon weaning, the reduction of hormonal levels stops milk production and promotes
apoptosis of epithelial cells, an event referred to as involution1,4.
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II.

BREAST CANCER
i.

Epidemiology

Breast cancer is the most commonly diagnosed cancer in women and it is one of the leading
causes of cancer deaths in the world. According to the World Health Organization, breast cancer
was responsible for 571,000 deaths in 2015. In the US, the National Cancer Institute estimates
255,180 new cases (15% of all new cancer cases) along with 41,070 deaths (6.8% of all cancer
deaths) for breast cancer in 2017. The incidence of breast cancer and mortality increase
dramatically with age. Breast cancer is most frequently diagnosed in middle-aged and older
women among women aged 55-64 (median age at diagnosed is 62)5.
The percent of female breast cancer deaths is highest among women aged 55-64 (median age
at death is 68). Women who are diagnosed at an advanced age may be more likely than younger
women to die of the disease. Five-year relative survival depends on the stage at which the cancer
is diagnosed. There are better chances of surviving five years after being diagnosed when the
breast cancer is detected earlier. Five-year relative survival is 99% for localized stage, 85% for
regional stage, and 27% for distant stage.
ii.

Classification

Breast cancer is a complex disease with multiple subtypes, each characterized by distinct
morphology, molecular profile, clinical behavior and treatment options. The majority of breast
cancer tumors (95%) are derived from the inner lining epithelium of the ducts or the lobules of the
breast. Breast cancer originating from the ducts are known as ductal carcinomas, while those
originating from the lobules are known as lobular carcinomas. The most common type of breast
cancer is ductal carcinoma. Ductal and lobular carcinomas are divided into two types based on
their histological appearance: 1. in situ, noninvasive neoplastic cells that are limited to the
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epithelial layer; 2. invasive carcinoma, which denotes a cancer that has moved through the basal
lamina of the epithelial layer and has invaded the surrounding stroma. Ductal invasive carcinoma
is the most common form of breast cancer and represents 80% of all breast cancer diagnoses6.
Breast cancers are classified into three clinical subgroups based on similarities in the gene
expression profile and molecular classification. The most common subtype accounts for 70-80%
of all the cases is estrogen/progesterone receptor positive (ER+/PR+) known as luminal breast
cancer. The second subtype is human epidermal growth factor 2 positive (HER2+ overexpressed
and amplified), which accounts for 15% of all the cases. Both luminal and HER2+ respond to
hormone and antibody therapy respectively. The third subtype is the basal-like or also known as
triple-negative (ER-, PR-, HER2-), which accounts for 15% of all the cases and responds to
chemotherapy and polymerase inhibitors7.

III.

EPITHELIAL-MESENCHYMAL TRANSITION
i.

Definition and Classification

Epithelial cells are polarized cells with strong adherent cell-cell and cell-basal lamina junctions.
The basement membrane separates the epithelial lining from the stroma or connective tissue. In
contrast, mesenchymal cells display fibroblast-like morphology, lack of cell-cell adhesions and
have the ability to migrate and invade adjacent tissues. The process by which epithelial cells dedifferentiate into mesenchymal cells is called epithelial-mesenchymal transition (EMT). EMT is a
biological process that involves a set of multiple and dynamic transitional states between epithelial
and mesenchymal phenotypes with a reverse process called mesenchymal-epithelial transition
(MET)8.
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EMT programs have been classified into 3 types; type 1 relates to embryo formation and
development; type 2 is related to tissue regeneration, organ fibrosis and wound healing; and type
3 is associated with cancer progression and metastasis8,9.
Type 3 EMT can be activated in epithelial cancer cells, causing them to downregulate adhesion
junctions, acquire invasive properties and develop metastatic growth characteristics. Epithelial
cancer cells that undergo full or partial EMT participate in cancer progression including invasion
through the basement membrane, migration through stroma and intravasation followed by
transport through the lymphatics or circulation. In addition, EMT confers a stem cell phenotype
and resistance to cell death, immunotherapy and chemotherapy8,10.
ii.

EMT-mediated changes in gene expression

During EMT, cancer cells oscillate between intermediary phases of epithelial and mesenchymal
phenotypes8. Epithelial cancer cells that undergo complete EMT suffer complex cellular and
molecular alterations such as changes in morphology, acquisition of motility and changes in gene
expression profile that ultimately promote invasiveness and metastasis. These events involve
reduction in epithelial proteins like cell-cell adhesion molecule E-cadherin, accompanied by the
upregulation of mesenchymal proteins such as Vimentin, N-cadherin, fibronectin and α-smooth
muscle actin which facilitate migration and invasion8,11.
iii.

EMT-inducing transcription factors

EMT is driven by several transcription factors including zinc-finger binding transcription factors
SNAIL1and SNAIL2; zinc finger E-box–binding homeobox ZEB1 and ZEB2; and basic-loophelix Twist in respond to a microenvironmental stimuli12. These EMT-inducing transcription
factors repress expression of genes associated with cell-cell adhesion, while activating genes
associated with the mesenchymal phenotype10. SNAIL1, SNAIL2 and TWIST repress the
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expression of E-cadherin, tight junction proteins (claudin and occludin) and epithelial-specific
intermediate filament proteins (cytokeratins)10,11. These factors activate the expression of
fibronectin, N-cadherin and genes encoding extracellular matrix proteins (collagen and matrix
metalloproteinases - MMPs) and drive cancer stem cell features11. ZEB factors are known to
repress directly E-cadherin and the tight junction associated signaling proteins ZO-1, and activate
N-cadherin and MMPs10,11.
iv.

EMT-inducing signaling pathways

EMT is induced in response to stimuli from the tumor microenvironment, like growth factors,
cytokines, hypoxia, and contact with the surrounding extracellular matrix (ECM)11. These stimuli
activate signaling pathways including transforming growth factor-β (TGF-β), Notch, WNT/βcatenin, Hedgehog and receptor tyrosine kinases which in turn activate EMT-transcription factors
to initiate the EMT process11,12.
TGFβ is the most well-characterized signaling pathway that induces EMT by acting through
SMAD-mediated and non-SMAD signaling11,12. SMAD-mediated signaling activates SMAD
factors (SMAD 2/3/4), resulting in an activated complex that interacts with several transcription
factors (SNAIL1, SNAIL2 and TWIST) to regulate genes involved in the EMT process. In
addition, SMADs directly activate the expression of some mesenchymal genes encoding
fibronectin, vimentin and collagen. TGFβ also induces non-SMAD signaling pathways like NFκB, Par6, small GTPases, PI3K/AKT/TOR and MAP kinase that regulate cytoskeleton
organization, cell survival, migration and invasion contributing to the EMT process13.
Receptor tyrosine kinases are activated by several growth factors including epidermal growth
factor (EGF), fibroblast growth factor (FGF), hepatocyte growth factor (HGF) and vascular
endothelial growth factor (VEGF), leading to the RAS–RAF–MEK–ERK MAPK signaling
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cascade to induce EMT. On the other hand, Notch, WNT/β-catenin and Hedgehog pathways
promote downregulation of E-cadherin levels11,13.
Hypoxia is as an example of a major external stimulus that leads to changes in mitochondrial
function, leading to the upregulation of hypoxia-inducible factor 1-α (HIF1α), hepatocyte growth
factor (HGF), SNAI1 and TWIST1 and activation of the Notch or NF-κB pathways12,13.
Inflammation also promotes EMT, involving cytokines such as interleukin-6 and TNF-α11.
Additionally, TNF-α promotes cancer invasion, angiogenesis and stemness properties associated
with EMT programs11–13. The pathways that induce EMT also involve microRNAs (miRNAs)11,12.
Specific miRNAs target mRNAs encoding adhesion junction and polarity complex proteins and
signaling mediators. For example, miR-194 represses N-cadherin expression, preventing cell
migration and invasion. The miR-200 family suppresses the EMT process by targeting
ZEB1/ZEB2 and maintaining E-cadherin expression12.

IV.

Metabolic Reprogramming

Cancer cells undergo metabolic alterations to adapt to the tumor microenvironment. Collectively
these alterations are referred as metabolic reprogramming, which confers growth and/or survival
advantages on cancer cells14. Metabolic reprogramming of cancer cells is associated with increased
nutrient uptake including glucose and glutamine, along with alterations of intracellular metabolic
pathways like glycolysis and tricarboxylic acid (TCA) cycle. In some cases, metabolic
reprogramming allows cancer cells to accumulate precursor molecules needed during rapid cell
proliferation, and to produce ATP as well as antioxidant metabolites, such as NADPH. In addition,
metabolic reprogramming promotes access to diverse metabolites that serve as cofactors or
substrates for enzymes involved in signaling pathways and gene regulation15. Finally, cancer cells
that undergo metabolic reprogramming are able to alter the composition of their tumor
7

microenvironment, affecting the behavior of neighboring cells like tumor-associated fibroblasts,
endothelial cells, and innate and adaptive immune system cells to favor tumor growth and
dissemination14,16.
i.

Mitochondrial Respiration

Most differentiated and nonproliferating cells metabolize glucose into pyruvate via glycolysis, and
then most of that pyruvate enters into mitochondria where it is converted to acetyl-CoA, which is
completely oxidized to carbon dioxide (CO2) in the tricarboxylic acid (TCA) cycle. The electrons
released from this oxidation process are transferred to NAD+ and FAD+, to generate 3 NADH and
one FADH2. These reduced cofactors are used to create a proton gradient across the mitochondrial
membrane by a pathway called the electron transport chain (ETC). The energy stored in this
gradient is used to drive ATP synthesis by a process called oxidative phosphorylation (OXPHOS).
In OXPHOS, oxygen must be present to receive electrons from the protein complexes as it is the
final electron acceptor. A maximum of 32 molecules of ATP (2 from the TCA cycle and 30 from
OXPHOS) are generated per two molecules of acetyl-CoA entered into the TCA cycle.
In a tumor there are regions with different nutrient and oxygen concentrations, driving selection
for those cancer cells that are able to adapt their metabolism to changing external factors.
Relatively quiescent cancer cells that reside within an oxygenated tumor microenvironment utilize
glucose preferentially for mitochondrial acetyl-CoA generation, which is then subjected to
oxidation in the TCA cycle and later OXPHOS for ATP production14. In fact, studies in breast and
cervical cancer cells showed that mitochondrial OXPHOs contributes more than 70% and 90%
respectively in overall ATP generation under normal conditions17. On the other hand, aggressive
and rapidly proliferating cancer cells switch to a glycolytic metabolism to generate ATP regardless
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of the presence of oxygen, a phenomenon referred to as "the Warburg effect" or aerobic
glycolysis18.
ii.

Aerobic glycolysis or “Warburg effect”

In the 1920s, the German physiologist Otto Warburg made an observation regarding tumor
metabolism. He showed that tumor tissue metabolizes more glucose compared to nonproliferating
normal tissue resulting in high lactate production even in the presence of oxygen. This observation
has come to be known as the “Warburg effect” or aerobic glycolysis. Most recently, studies have
shown that proliferating cancer cells exhibit increased glucose uptake and glycolytic flux 14. Most
of the pyruvate from glycolysis is converted to lactate rather than be transported into the
mitochondria to maintain oxidative phosphorylation. Although glycolysis has a low efficiency to
produce ATP (2 molecules per glucose), the rate of ATP synthesis is faster compared to OXPHOS.
Consequently, by increasing glucose uptake and glycolytic flux, the amount of ATP produced from
glycolysis can surpass the amount produced from OXHPHOS. Additionally, glucose catabolism
provides metabolic intermediates needed for rapid cell growth, and reduces oxygen dependency
and reactive oxygen species (ROS) production. Furthermore, lactate generated by glycolytic
cancer cells acidifies the extracellular microenvironment which facilitates tumor cell migration
and invasion19. Recent studies have shown that the Warburg effect phenomenon is typical in
proliferating tumor cells and also in some stromal cells like cancer-associated fibroblasts
(CAFs)14,18.
iii.

Reverse glycolysis or “Reverse Warburg effect”

In a single tumor there are numerous heterogeneous cell populations. Thus, both mitochondrial
respiration and aerobic glycolysis contribute differently to each population and favor tumor growth
and survival under different conditions. Cancer cells have flexible metabolic phenotypes. Under

9

nutrient/glucose-limited conditions, glycolytic cancer cells can alter metabolism, via activation of
signaling pathways and transcription factors, and restore partly suppressed OXPHOS20,21. Those
cancer cells able to perform oxidative metabolism and particularly located in close proximity to
blood vessels, can utilize energy-rich fuels (such as pyruvate, ketone bodies, fatty acids and lactate)
produced by their neighboring cells (proliferating cancer cells and CAFs) to fuel mitochondrial
OXPHOs for ATP production22. This utilization of lactate and other energy-rich fuels by cancer
cells capable of using oxidative metabolism is referred to as the “Reverse Warburg effect”23.
Tumor cancer cells affect their tumor microenvironment to maintain “Reverse Warburg effect”.
For example, tumor cells have been shown to secrete hydrogen peroxide, which causes oxidative
stress in neighboring CAFs. This induces aerobic glycolysis accompanied with high lactate
production in CAFs, and the lactate in turn fuels OXPHOS in oxidative cancer cells24.

V.

Lactate Metabolism
i.

Lactate metabolism key players

Highly glycolytic cancer cells produce high amounts of pyruvate that is converted into lactate by
tetrameric isozymes called lactate dehydrogenases (LDHs). These isozymes are formed by the
combination of two different subunits, LDHA and LDHB. The subunit LDHA has a higher affinity
for pyruvate and a higher Vmax for pyruvate reduction than LDHB. As a result, the tetramer with
more LDHA subunits catabolizes pyruvate to lactate and produces NAD+, which is essential for
glyceraldehyde 3-phosphate dehydrogenase (GAPDH) in glycolysis. By contrast, tetramers rich in
the LDHB isoform convert lactate to pyruvate, which allows cells to use lactate as a nutrient source
for oxidative metabolism and/or for gluconeogenesis/reverse glycolysis. LDHB is ubiquitously
expressed, especially in oxidative cardiac muscle, whereas LDHA is the predominant isoform
found in Type II skeletal muscle fibers and other highly glycolytic tissues25.
10

Lactate levels within the extracellular tumor microenvironment are determined by the balance of
lactate uptake and lactate export by tumor and tumor-associated cells. Lactate is transported across
the plasma membrane of cancer cells through monocarboxylate transporters (MCTs). MCTs are
proton-linked transporters and possess different affinities for lactate, which, in turn, partly
determines the direction of lactate flux. Thus, secretion of lactate is through the low-affinity lactate
transporter MCT4 (Km≈28 mmol/L) and lactate uptake primarily occurs through the high-affinity
MCT1 transporter (Km≈1– 3.5 mmol/L)26. In normal physiology, MCT4 is highly expressed in
glycolytic tissues like type IIB skeletal muscle fibers and astrocytes, whereas MCT1 is highly
expressed in oxidative tissues, including cardiac muscle, Type I skeletal muscle fibers, and
neurons.
ii.

Lactate as a nutrient source

More than a waste product of glycolysis, lactate was recently identified as a major energy fuel for
oxidative tumor cells. Lactate, secreted by glycolytic tumor cells through the lactate exporter,
MCT4, may be taken up by oxidative tumor cells through lactate importer MCT1, converted into
pyruvate by LDHB and used as a fuel for oxidative metabolism27,28. Thus, oxidative tumor cells
spare glucose which may, in turn, reach glycolytic tumor cells. This “lactate shuttle” is part of the
metabolic symbiosis between tumor cells and it is an important component in the “Reverse
Warburg effect” phenomenon described in different types of cancer including breast cancer 27–30.
iii.

Lactate signaling molecule

Lactate plays a critical role in cancer progression and metastasis by promoting cancer cell
migration, immune escape and angiogenesis

31–33

. Extracellular lactate promotes tumor cell

migration and angiogenesis by inducing the secretion of the cytokine IL-8 and the vascular
endothelial growth factor (VEGF) by endothelial cells
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31,34,35

. Moreover, lactate is able to block

immune surveillance by inhibiting the differentiation of monocytes and natural killer cells33,36.
Also, the secretion of lactate through MCTs releases H+, decreasing the extracellular pH that
affects T-cell function and provokes local inflammation37,38.
Recently two signaling pathways have been identified where lactate acts as a “signaling molecule”
to promote angiogenesis and tumor growth. First, lactate inhibits prolylhydroxylase 2 (PHD2), the
enzyme that hydroxylates HIF1α, inhibiting its ubiquitination and subsequent proteasomal
degradation. Thus, lactate promotes angiogenesis and other HIF1α-related effects in the absence
of hypoxia39. Second, lactate also inhibits the proteosomal degradation of the tumor promoter, NMyc Downstream Regulated Gene 3 (NDRG3), another target of PHD2. Also, lactate binds
directly to NDRG3 activating the Raf-ERK pathway to promote angiogenesis and cell growth
during hypoxia40.
iv.

GPR81

G protein-coupled receptor-81 (GPR81) has been identified as the endogenous receptor for lactate.
Lactate activates GPR81 with a EC50 value of 5 mM, which is within the physiologic
concentration range (1 to 20 mmol/L) of lactate within breast tumors. Also known as Hydroxy
Carboxylic Acid Receptor 1 (HCAR1), GPR81 is part of the HCAR family that consists of three
highly homologous receptors; GPR81 (HCAR1), GPR109a (HCAR2) and GPR109b (HCAR3),
which are regulated by the specific agonist, L-lactate, 3-hydroxybutyrate and 3-hydroxyoctanoate,
respectively41. In normal cell types (e.g., adipocytes), GPR81 is coupled to Gi/q, and activation of
the receptor by L-lactate results in decreased cellular levels of cAMP and increased cellular levels
of Ca2+. This receptor has been mainly studied in adipocytes, in which extracellular lactate
specifically activates GPR81 to decrease the cAMP production and ultimately reduce lipolysis42.
GPR81 is receiving increasing attention in the cancer field as a result of its upregulated expression
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in several types of cancers like pancreas, colon, liver, breast, lung and cervix which in many cases
the correlates with tumor growth, chemoresistance and metastasis 43–46. In particular, one recent
study showed that GPR81 regulates lactate transporters MCT1 and MCT4 in pancreatic cancer
cells and promotes cell growth/survival under nutrient stress conditions 44.

VI.

Significance
Although, there is an increasing interest in the lactate metabolism of cancer, there are few

studies on lactate metabolism in the context of metastatic transformation. Since EMT induces
metastatic transformation, in chapter 3 we studied the metabolic reprogramming induced by EMT
in breast cancer. We analyzed the alterations in the lactate metabolism of two epithelial breast
cancer cell lines and their respective post-EMT mesenchymal breast cancer cell lines. In addition,
we studied the role of the lactate importer MCT1 in the epithelial breast cancer cells.
The lactate receptor GPR81 has been shown to promote cancer progression. In chapter 4,
we studied the expression of GPR81 in human breast cancer tissues and in a EMT breast cellular
model. We also studied the role of this receptor in epithelial breast cancer cells and its potential as
a therapeutic target.
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CHAPTER 2

MATERIALS AND METHODS

14

Cell culture
BT-474 and MCF-7 cell lines were obtained from the American Type Culture Collection
(Manassas, VA). EMT in MCF-7 and BT-747 cells was induced using prolonged mammosphere
culture method as reported previously47,48. BT-474 and MCF-7 and their corresponding EMTderived BT-474-M and MCF-7-M cells were grown in DMEM/F-12 containing 10% heat
inactivated FBS (Gibco, Grand Island, NY) and 1× MycoZap™ Plus-CL antibiotic
(Lonza,Walkersville, MD). BT-474 and MCF-7 cells were additionally supplemented with 1×
Insulin–Transferrin–Selenium solution (Gibco, Grand Island, NY). All cells were incubated at 5%
CO2 and at 37 °C.
Physiological modified medium and drugs
RPMI 1640 Medium Modified without l-Glutamine, without Amino acids and Glucose (US
Biological, Swampscott, MA) was supplemented with 5 mM D-glucose, 2.5 mM L-glutamine
(Sigma, St. Louis, MO), 1× MEM essential and non-essential amino acid mixtures, 10% heat
inactivated FBS, 15 mM HEPES (Gibco, Grand Island, NY); 0.5 mM sodium pyruvate, chemically
defined lipid mixture 1, 15 mM sodium bicarbonate, 1 mM Na-lactate (Sigma, St. Louis, MO) and
1× MycoZap™ Plus-CL antibiotic (Lonza,Walkersville, MD).
RPMI-1640 Medium Modified with L-glutamine, without phenol red and sodium bicarbonate
(Sigma, St. Louis, MO) was used in assays where cells were treated with β-Estradiol or Tamoxifen.
MCT1 inhibitor SR 13800, β-Estradiol and Tamoxifen (Tocris Bioscience, Bristol, UK) solutions
were made using ethanol and were used at concentrations of 100 nM, 10 nM and 1 µM,
respectively.
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3-dimensional culture
Corning™ Matrigel™ GFR (Fisher Scientiic) or Matrigel™ (Corning) was used as culture matrix
following a modified version of the previously described protocol for 3-dimensional on-top
assay49.

Twenty-four-well

plates

were

coated

with

200ul

of

the

mix

of

1:1

Matrigel™/Physiological modified medium supplemented with 1x Insulin–Transferrin–Selenium
solution (Gibco, Grand Island, NY) and kept at 37°C for 30 minutes to allow the Matrigel™ to
solidify. All cell lines were suspended in physiological modified medium supplemented with 1x
insulin and seeded into the coated twenty-four-plates. Epithelial and mesenchymal cells were
seeded in 250µl at 100, 000 cells/well and 20, 000 cells/well, respectively, and incubated at 37°C
for 30 minutes to allow cell attachment to the Matrigel. All wells were overlaid with 250µl of
physiological modified medium containing 4% Matrigel™. Culture medium was replaced with
fresh medium daily and cells were used for each assay after seven days, unless otherwise indicated.
Imaging of 3-dimensional structures
Cells were cultured in 3-dimensional Matrigel and glass bottom 24-well plate (MatTek
Corporation, MA) for seven days. Phase contrast images of the 3-dimensional structures of
epithelial and mesenchymal cells were imaged using a Zeiss Axio Observer inverted microscope
(Carl Zeiss MicroImaging Inc., Thomwood, NY) equipped a QImaging Retiga EXi CCD digital
camera (QImaging, Surrey, BC). For immunofluorescence images cell lines grown in 3dimensional Matrigel at the seventh day were fixed in 2% formaldehyde in 1X PBS for 20 minutes.
Cells were washed with 1X PBS and then treated with 0.1% Triton-X 100 for 10 minutes. Cell
were washed with 1X PBS and blocked with 1% bovine serum albumin (BSA) for 20 minutes.
After blocking, cells were incubated with F-actin-staining phalloidin staining solution for 20
minutes at room temperature. Phallotoxin staining solution was prepared with 5µl Alexa-488
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Phallotoxin (Invitrogen, Carlsbad, CA) stock in 200µl 1X PBS for each well to be stained.
SYTOXTM orange dye (Invitrogen, Carlsbad, CA) was used to stain nuclei. Images were captured
using a Zeiss Pascal confocal system with a 40X 1.2 NA objective (Carl Zeiss Microscopy,
Narashige, MN).
Transient transfection of siRNA
MCF-7 cells were seeded in 250ul at a density of 150, 000 cells/well in twenty-four-well plates
coated with 200ul of the mix of 1:1 Matrigel™/Physiological modified medium supplemented
with 1x Insulin–Transferrin–Selenium solution (Gibco, Grand Island, NY) and transiently
transfected with Trilencer-27 human siRNA (siNT, siGPR81 “B” and siGATA3 “A”) at a final
concentration of 10 nM (Origene, Rockville, MD) with Lipofectamine™ RNAiMAX transfection
reagent (Thermo Scientific, Rockford, IL). After 8 hours of transfection cells were overlaid with
250µl of physiological modified medium containing 4% Matrigel™. Culture medium was replaced
with fresh medium every day and cells were used for each assay after 72 or 96 hours after
transfection.
Growth and viability assays
For a seven-day growth curve, epithelial and mesenchymal cells were plated at a density of
100,000 cells/well and 20,000 cells/well, respectively in 3-dimensional Matrigel™ culture. MCF7 cells were seeded at a density of 150, 000 cells/well for transient transfection and treatments with
MCT1 inhibitor SR 13800 or Tamoxifen (Tocris Bioscience, Bristol, UK). Cells were recovered
from Matrigel by incubating them with 5 mM EDTA (Gibco, Grand Island, NY) in ice cold 1x
PBS for 30 minutes at 4°C and centrifuged for 5 minutes at 1000 rpm. Recovered cells were
digested with 0.25% trypsin for 4 min and resuspended in DMEM with 10% FBS. The cell number
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was calculated on hemocytometer at specific time point. Cell number viability assays were
performed three times for each cell group.
Real-time qPCR and primers
Total RNA was isolated from cell lines using TRIzol Reagent (Ambion RNA, Carlsbad, CA),
following the manufacturer’s instruction. cDNA was synthesized 1 μg of total RNA using
iSCRIPT cDNA synthesis kit (Bio-Rad, Hercules, CA). SYBR green based SsoFast EvaGreen
Supermix (Bio-Rad, Hercules, CA) was utilized to perform real-time PCR from 50ng of cDNA.
Gene expression was normalized to TATA-box binding protein 1 (TBP1) using 2−ΔCt method.
Specificity of the primer sets was confirmed by melting curve analysis. Primer sequences were
listed in Appendix section.
cDNA Arrays
Real-time qPCR was performed in two TissueScan™ breast cancer and normal tissue cDNA arrays
I and II (Origene, Rockville, MD). Gene expression was normalized to normal tissue using 2−ΔCt
method.
Real-time metabolic analysis
Simultaneous multiparameter metabolic analysis of all four cell lines in culture was performed in
the Seahorse XF96 extracellular flux analyzer (Seahorse Bioscience, Billerica, MA). Epithelial
and mesenchymal cells were seeded in Seahorse 96-well XF cell culture microplate at 15,000
cells/well and 8,000 cells/well, respectively, and pre-incubated at 37°C in 5% CO2. Following 48
hours of incubation, the culture medium was replaced with assay media (unbuffered Seahorse XF
Base medium supplemented with 5 mM D-glucose, 0.5 mM L-glutamine, 0.1 mM sodium pyruvate
and 1 mM Na-lactate, pH 7.4) one hour before the assay in a non-CO2 incubator and for the
duration of the experiment. Mitochondrial complex inhibitors (1 µM oligomycin, 1 μM FCCP, 0.5
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μM rotenone) were preloaded in the injection ports. Three baseline measurements of oxygen
consumption rate (OCR) and extracellular acidification rate (ECAR) were made and were
averaged to give the 100% starting value. After establishing the OCR and ECAR baselines,
mitochondrial complex inhibitors (oligomycin, FCCP, rotenone) were injected consequently and
after a short period of mixing, OCR and ECAR measurements were made using photodetectors
with specific excitation and emission wavelengths of oxygen (532/650 nm) and protons (470/530
nm; 28). These experiments were performed two times, each with ten samples per cell type. The
data were normalized by cell number.
Glucose uptake and lactate production
Epithelial and mesenchymal cells were plated at a density 100,000 cells/well and 20, 000 cells/well
in 3-dimensional Matrigel™ culture for seven days. For transient transfection, MCF-7 cells were
seeded at a density of 150, 000 cells/well and medium was changed daily. Glucose and lactate
concentrations in the culture medium were determined by fluorometric-based Glucose Assay Kit
and Lactate Assay Kit (BioVision, Inc., Milpitas, CA) according to the vendor’s instructions using
Synergy 2 Multi-Mode Microplate Reader (BioTek, Winooski, VT). The amount consumed or
produced by cells was determined by comparing the concentration in the medium incubated
without cells and then normalized to cell number. These assays were performed three times with
two experimental replicates for each cell group.
Western blot and antibodies
Cells were collected form 3-dimensiona Matrigel™ culture (as described previously) and lysed
with RIPA buffer (TEKnova, Hollister, CA) containing Halt Protease and Phosphatase Inhibitor
Cocktail (Thermo Scientific, Rockford, IL). The lysates were clarified by centrifugation at 4 °C
for 10 min at 12,000 ×g. The concentration of protein in the supernatants was measured using BCA
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assay (Thermo Scientific Pierce, Rockford, IL). Total proteins (20 μg/lane) were separated on a
10% SDS-PAGE and were transferred to nitrocellulose membrane. The membranes were blocked
with 5% BSA in 1× TBST (β-actin, LDHA and LDHB) or with 5% non-fat milk (MCT1, MCT4
and Cleaved PARP) and subsequently incubated with primary and secondary antibodies according
to the vendor’s instructions. Blots were visualized by using Amersham ECL prime (GE Healthcare
Life Sciences, Buckinghamshire, UK) and imaged using G:box imaging system (SynGene,
Cambridge, UK). Primary antibodies to LDHA (1:10,000) was purchased from Cell Signaling
Technology (Danvers, MA); Cleaved PARP (1:1000 from Cell Signaling Technology (Danvers,
MA) was a gift by Dr. K. Claffey, Dept of Cell Biology and Center for Vascular Biology, UConn
Health); β-actin (1:2500) and MCT1 (1:1000) were purchased from Abcam (Cambridge, MA);
LDHB (1: 10,000) was purchased from OriGene (Rockville, MD). MCT4 (1:1000) was purchased
from Millipore (Billerica, MA). All images were imported to Image J for pixel grayscale intensity
analysis. Western blot analysis was performed three times using two independent protein samples
for each cell group.
Nuclear Magnetic Resonance (NMR) Spectroscopy and Data Analysis
Cells were collected form 3-dimensional Matrigel™ culture (as described previously) and lysed
with 1:1:1 methanol/chloroform/water in sequence with 5 seconds of gyration between additions.
In order to optimize chemical extraction, non-trypsin-based methods were employed as follows50.
A 10 µL sample was then removed for cell counting. Resulting lysed solution was then allowed to
separate overnight at 4°C to form resultant aqueous and organic layers. Aqueous layer containing
metabolites of concern were then manually extracted and resulting solution was subjected to
addition of Chelex (approx. 3mg/mL) for removal of divalent ions, which was then removed
through vacuum filtration using Buchner filter. Solution was then lyophilized overnight to form
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solid components. 800 µL of D2O with 10 mM EDTA and 1 mM 4,4-dimethyl-4-silapentane-1sulfonic acid (DSS) was added and solution was centrifuged at 3000RPM for 5 minutes prior to
placement in standard 5 mm NMR tube for 1H NMR.
1

H NMR experiments were performed on 500 MHz Agilent spectrometer with HCN cold probe

and a VNMRS console. Default pre-saturation pulse sequences were utilized with the following
parameters: pulse-width = 7.2 µs, sweep-width = 8389.26 Hz, 2460 complex points, D1 = 1.5 s,
SATPWR = 6 dB on H2O signal, and 64 transients. Resulting 1H NMR underwent Fourier
Transformation and data was further analyzed in MestReNova NMR software, version 9.0.0.
Processing template for all spectra had the following time domain corrections: drift correction to
tail points of 5% and apodization through an exponential of 1.5 Hz. The frequency domain had
global phase correction and a baseline correction using Bernstein polynomial of n=3. Reference
signal was set as the singlet produced off of DSS at 0 ppm. Lactate and Pyruvate were identified
on the spectra through prior titration analyses and the absolute area under the curve was used for
their methyl groups with respect to methyl groups found off of DSS with the usage of Line-Shape
analysis. These areas were used to calculate concentrations by a ratio of the absolute area to the
number of protons in the signal used. Resulting concentrations in millimolar were then exported
into an Excel spread sheet containing cellular counts to determine a normalized concentration per
number of cells.
Statistical analysis
Ordinary one-way ANOVA followed by Sidak’s multiple comparison post-test or two-way
ANOVA was performed to determine statistical significance. P < 0.05 was considered to be
significant. Statistical analysis was performed using GraphPad Prism software (La Jolla, CA).

21

CHAPTER 3

EPITHELIAL-MESENCHYMAL TRANSITION INDUCES CHANGES IN THE
LACTATE METABOLISM OF BREAST CANCER CELL LINES

22

I.

Abstract

Lactate is both a metabolite of glycolysis and a component of several signaling pathways.
Although recent studies indicate that lactate is a critical regulator of cancer development, very
little is known about lactate metabolism in the context of metastatic cancer. Epithelialmesenchymal transition (EMT) promotes metastasis by inducing invasive properties in epithelial
tumors. To determine whether EMT induces metabolic alterations, we have studied two epithelial
breast cancer cell lines (MCF-7 and BT-474) and their respective EMT-induced mesenchymal
progeny (MCF-7 M and BT-474 M) for changes in lactate metabolism. Metabolic analysis
revealed that EMT induced an enhanced glycolytic profile in mesenchymal breast cancer cells
along with the overexpression of glucose transporters (GLUT3, GLUT12), lactate dehydrogenases
(LDHA, LDHB) and monocarboxylate transporter 4 (MCT4). In contrast, epithelial breast cancer
cells preferentially used oxidative phosphorylation (OXPHOS) to produce ATP. These aerobic
epithelial breast cancer cells highly expressed the estrogen receptor α (ERα) and the
monocarboxylate transporter 1 (MCT1). We found that the epithelial breast cancer cells but not
the mesenchymal breast cancer cells imported lactate through MCT1 and used it as an alternative
nutrient to support cell growth. The strong expression of MCT1 in epithelial breast cancer cells
was regulated by ERα signaling pathway and the transcription factor GATA3. In addition, the cotreatment of epithelial breast cancer cells with Tamoxifen and MCT1 inhibitor inhibited cell
proliferation to a significantly greater extent than with either drug by itself. Our study suggests the
potential of MCT1 as a therapeutic target to treat ER-positive epithelial breast cancer.
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II.

Introduction

Invasive breast cancer (IBC) is the predominant form of cancer among women worldwide and the
second cause of cancer-related deaths in women in the United States51 5. The most common type
of IBC, called Luminal A, is characterized by an adhesive epithelial phenotype and overexpression
of the estrogen receptor α (ERα). Although Luminal A IBC is a relatively indolent, non-aggressive
form of cancer, failure of early detection is significantly associated with metastatic disease, which
in turn is responsible for the majority of deaths in breast cancer patients.
Metastatic dissemination of IBC involves a succession of complex events that ultimately
lead to the colonization of distant organs52. Either complete or partial epithelial-mesenchymal
transition (EMT) has been implicated in the earliest stages of metastasis8. EMT allows for the
detachment of cells from the main tumor mass, and increases motility and invasiveness of tumor
cells, coupled to increased autonomous production of extracellular matrix. Differing degrees
and/or modes of EMT are orchestrated by a range of transcriptional and epigenetic mechanisms
among the heterogeneous population of cells within a tumor. The process of EMT can be induced
by exposure of cancer cells to an altered microenvironment (e.g., hypoxia, increased cytokines)
that is imposed by the tumor itself (or a subpopulation thereof), by surrounding cells (e.g.
macrophages) in response to a growing tumor, and/or by systemic physiology that has been altered
(e.g., by obesity). Additional somatic mutations in highly proliferative cells also likely contribute
to a changing microenvironment and/or the responsiveness of tumor cells to the microenvironment
10 12

.
Cancer cells frequently exhibit increased glucose uptake, glycolytic rates and lactate

production in the presence of oxygen, a process referred to as “aerobic glycolysis” or “Warburg
effect”
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. A large body of recent studies revealed that aerobic glycolysis and other metabolic
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changes allow cancer cells to accumulate building blocks for the biosynthesis of macromolecules
that are used in anabolic pathways, while simultaneously satisfying the high energy demands and
maintaining redox balance needed for cell proliferation53. These metabolic changes are collectively
referred to as “metabolic reprogramming”, now considered a hallmark of cancer cell biology14,54.
Most studies on metabolic reprogramming have been performed in the context of transformation
per se, i.e., the comparison of metabolic pathways in non-neoplastic cells to those in their
neoplastic counterparts55–57. More recent studies have also demonstrated that metabolic
reprogramming occurs within epithelial cancer cells that partially or completely transition to
mesenchymal cancer cells. Some studies have indicated that metabolic reprograming contributes
to the acquisition and maintenance of the mesenchymal phenotype in breast cancer cells and this
cell type exhibits a specific metabolic signature associated with poor clinical outcome in breast
cancer patients 58,59.
We previously reported that prolonged 3-dimensional mammosphere culture induced EMT
in two distinct epithelial breast cancer cell lines, MCF-7 and BT-474 cells, generating stable
populations of mesenchymal cancer cells, termed MCF-7M and BT-474M cells, respectively47,48.
Using standard 2-dimensional culture on plastic dishes and a standard tissue culture medium
(DMEM/F12) containing supra-physiological levels of several nutrients (especially glucose), we
characterized these four cell lines with respect to metabolism by assaying the expression of
enzymes and specific metabolite transporters associated glycolysis and associated side-pathways,
and in terms of glucose uptake and lactate production. These analyses indicated that both epithelial
MCF-7 and BT-474 cells are less glycolytic than the two mesenchymal MCF-7M and BT-474M
cell lines, but express higher levels of enzymes involved in reverse glycolysis and certain
glycolytic side-pathways. In the current study, we directly examined the degree of oxidative vs
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glycolytic metabolism in these 4 cell lines, using a culture system that involves both a 3dimensional Matrigel matrix and media containing the physiological levels of glucose (5 mM),
lactate (1 mM), glutamine (0.5 mM) and pyruvate (0.1 mM). In addition, we further examined
metabolic differences in lactate flux and utilization in these phenotypically different cell lines.
Finally, we showed that MCT1 is required for lactate import and survival of the epithelial, but not
mesenchymal, breast cancer cells.

III.

Results

Epithelial And Mesenchymal Phenotypes In 3-Dimensional Culture
A major objective of this study was the characterization of aspects of metabolism in the
two epithelial MCF-7 and BT-474 cell lines and the corresponding post-EMT mesenchymal MCF7M and BT-474M progeny within a culture system that was more physiologically-relevant and in
which specific nutrients were better defined. Thus, the four cell lines were cultured within a 3dimensional Matrigel configuration as described by Bissell and colleagues49. In addition, the
culture medium contained physiological levels of glucose (5 mM), lactate (1 mM), glutamine (0.5
mM) and pyruvate (0.1 mM), with medium changed daily, unless noted otherwise. Note that media
was supplemented with 10% FBS, so that final concentrations of these nutrients was moderately
higher than the values stated above. Note also that medium was changed daily as opposed to being
constantly perfused, so that the levels of these nutrients were subphysiological by the 23rd hour.
Under these conditions (termed MPM culture, for Matrigel & Physiological Medium), both
epithelial cell lines grew as tightly adherent spheroids for 1 week (Figure 3.1. A; “E” boxes). The
two mesenchymal cell lines also formed tight spheroids initially, but after 2 days began invading
the Matrigel (Figure 3.1. A; “M” boxes).

26

After 1 week of MPM culture, cells were examined for the expression of specific epithelial,
mesenchymal, EMT-related and stem cell-like markers. Epithelial spheroids maintained a high
level of expression of the epithelial zonula adherent protein, E-cadherin, and the Luminal A-related
transcription factor, GATA3 (Figure 3.1 B). Epithelial cells also expressed relatively high levels
of the hormone receptors, ERα, PR and/or HER2 (Figure 3.1 B). In contrast, mesenchymal cells
showed no or very low expression of E-cadherin, GATA3 and the three hormone receptors.
Mesenchymal cells expressed high levels of the mesenchymal marker, Vimentin, along with EMTrelated transcription factors, Zeb 1 and Zeb 2 (Figure 3.1. B). Finally, the two epithelial cell lines
displayed high CD24 but low CD44 expression consistent with a mammary cell differentiated
phenotype, whereas the two mesenchymal cell lines displayed high CD44 expression and low
CD24 expression, consistent with a less differentiated, “breast cancer stem cell” phenotype (Figure
3.1. B). The mesenchymal cells also expressed a mammary stem cell phenotype with high
expression of integrin α6 (CD49f) and the loss of the proto-oncogene c-Kit expression60–62 (Figure
1B). Both mesenchymal MCF-7M and BT-474M cell lines had a higher rate of proliferation, along
with elevated expression of mRNAs encoding cyclin B1 and Ki67 (Figure 3.2. A-B). These data
are consistent with our previous findings in these cells, both in 2-dimensional cell culture and after
orthotopic transplantation into mice47,48.

27

28

Figure 3.1. Epithelial MCF-7 and BT-474 and mesenchymal MCF-7M and BT-474M breast
cancer cells in 3-dimensional Matrigel culture.
Top: phase contrast images of epithelial (E) and mesenchymal (M) cells in 3-dimensional Matrigel
with physiological modified medium (MPM) for 7 days. Bottom: fluorescence microscopy images
of 3-dimensional structures of epithelial and mesenchymal cells. Green: phalloidin staining of Factin. Red: nuclei counterstained with SYTOXTM orange nucleic acid. Scale bar, 10μm. B. Realtime qPCR analysis of epithelial markers, E-cadherin and GATA3; mesenchymal marker,
vimentin; hormone/growth factor receptors, ER, PR and HER2; EMT transcription factors, ZEB1
and ZEB2; breast cancer and mammary epithelial stem cell markers, CD24, CD44, CD49f and cKit in BT-474, BT-474M, MCF-7and MCF-7M cells. Results are presented as mean ± S.E.M. from
three independent experiments (n>6) *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001
(ordinary one-way ANOVA).
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Figure 3.2. EMT-induced mesenchymal MCF-7M and BT-474M breast cancer cells
exhibited high cell proliferation rate in 3-dimensional Matrigel culture.
A. Increase in viable cell counts for epithelial (E) and mesenchymal (M) breast cancer cells at
days 3, 5 and 7 of culture after subtracting the initial cell number. B. Real-time qPCR analysis of
proliferation markers: cyclin B1 and Ki67. Results are presented as mean ± S.E.M. from three
independent experiments (n=6) *p < 0.05; **p < 0.01; ***p < 0.001 (two-way ANOVA).
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Epithelial MCF-7 And BT-474 Breast Cancer Cells Are More Oxidative, Whereas Post-EMT
Mesenchymal MCF-7M And BT-474M Breast Cancer Cells Are More Glycolytic
Subsequent studies investigated whether metabolic reprogramming is linked to EMT as
assessed in breast cancer cells culture in physiological medium. Energy metabolism in the two
epithelial MCF-7 and BT-474 cell lines and the two post-EMT mesenchymal MCF-7M and BT474M cell lines was examined in real time by the assay of oxygen consumption rate (OCR; a
measure of mitochondrial oxidative phosphorylation), extracellular acidification rate (ECAR; a
measure of glycolysis linked to the export of lactate anions and protons) and the dependency on
mitochondrial respiration for ATP production (see Chapter 2 Methods & Materials). Epithelial
cancer cells exhibited robust basal OCR but a low ECAR, whereas mesenchymal cells consumed
oxygen at a lower rate and showed a significantly higher ECAR (Figure 3.3. A). We further
explored mitochondrial function between epithelial and mesenchymal breast cancer cells by
determination of ATP-coupled respiration and maximal respiration capacity. Epithelial cancer
cells showed significantly higher mitochondrial ATP production and a greater maximal respiratory
capacity than mesenchymal cancer cells (Figure 3.3. B). Thus, the metabolism of both post-EMT
mesenchymal cell lines was shifted more towards aerobic glycolysis.
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Figure 3.3. EMT-induced BT-474M and MCF-7M mesenchymal breast cancer cells
exhibited a more glycolytic profile compared to their parental epithelial MCF-7 and BT-474.
Epithelial (E) and mesenchymal (M) cells were seeded on a Cell-Tak-treated XF24 cell culture
plate. Data were obtained with the XF Extracellular Flux Analyzer (Seahorse Bioscience). A.
Metabolic phenotype plot of basal oxygen consumption rate (OCR) vs. basal extracellular
acidification rate (ECAR) measurements. B. Schematic representation of the mitochondrial
function assay. After establishment of baseline OCR, sequential injection of oligomycin (ATP
synthase inhibitor), FCCP (mitochondrial uncoupler) and rotenone plus antimycin A (complex I
and III inhibitors, respectively) allowed for the determination of ATP-linked Respiration and
Maximal Respiratory Capacity. Results are presented as mean ± S.E.M. of two different
experiments (n=16) *p < 0.05; **p < 0.01; ***p < 0.001 (two-way ANOVA).
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Efficient Glycolysis and Lactate Export By Mesenchymal Cells
Consistent with a more glycolytic phenotype, both MCF-7M and BT-474M mesenchymal
cells displayed elevated glucose uptake (Figure 3.4. A), along with elevated expression of mRNAs
encoding GLUT3 and GLUT12, in addition to robust expression of GLUT1 mRNA observed in
all 4 cell lines (Supplemental figure 3.1. A). Aerobic glycolysis is associated with the reduction
of pyruvate to lactate anion coupled to the oxidation of NADH to NAD+ by lactate dehydrogenase
A (LDHA)-rich tetramers. The lactate anion and a proton undergo co-transport out of the cell
through the monocarboxylate transporters (MCTs; primarily MCT4). The mesenchymal MCF-7M
and BT-474M cells exported higher levels of lactate than the epithelial cells (Figure 3.4. B), and
expressed high levels of MCT4 mRNA and protein (Figure 3.4. C-D). Both LDHA and LDHB
protein expression were elevated in the mesenchymal MCF-7M and BT-474M cell lines (Figure
3.4. E-F). NMR analysis revealed that the steady-state levels of intracellular pyruvate and lactate
were very low in the two mesenchymal cell lines under MPM conditions (Figure 3.4. G-I).
Together, these findings demonstrate that both of the post-EMT mesenchymal cell lines rely more
heavily on the rapid metabolism of glucose through glycolysis, followed by efficient conversion
of pyruvate to lactate and the export of lactate.
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Figure 3.4. EMT-induced BT-474M and MCF-7M mesenchymal breast cancer cells
exhibited increased lactate production along with upregulation of lactate dehydrogenases
and downregulation of specific lactate transporter.
A-B. Glucose consumption and lactate production rates of epithelial (E) and mesenchymal (M)
breast cancer cells. Real-time qPCR analysis and protein expression of C-D. lactate transporters:
MCT1 and MCT4; E-F. lactate dehydrogenases: LDHA and LDHB in epithelial (E) and
mesenchymal (M) breast cancer cells cultured in 3-dimensional Matrigel with physiological
modified medium for 7 days. β-actin was used as a loading control. G. NMR profile of lactate
doublet, 1.31 ppm, 1.32ppm. pyruvate profile: singlet, 2.37 ppm. H-I. Intracellular lactate and
intracellular pyruvate of epithelial (E) and mesenchymal (M) breast cancer cells cultured in 3dimensional Matrigel for 7 days using NMR analysis. The bars represent the mean ± S.E.M. of
three independent experiments; (n>4) *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001
(ordinary one-way ANOVA).
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Lactate As A Potential Nutrient In Epithelial Cells
Both epithelial cell lines also exported lactate under MPM culture conditions, albeit at a
significantly lower rate than the mesenchymal cells (Figure 3.4. B). In contrast to the
mesenchymal cell lines, both epithelial cell lines expressed the lactate and pyruvate transporter,
MCT1, at relatively high levels, but expressed the lactate exporter, MCT-4, at very low levels
(Figure 3.4. C-D). Additionally, NMR analysis indicated higher intracellular pools of pyruvate
and lactate in both epithelial cell lines (Figure 3.4. G-I). Thus, the two epithelial cell lines maintain
an accessible pool of pyruvate for mitochondrial respiration and an accessible pool of lactate that
could be converted to pyruvate if needed. As stated above, although the LDHB mRNA levels are
low in both epithelial cell lines, LDHA and LDHB protein levels were readily detectable by
immunoblot (Figure 3.4. E-F), indicating some capacity for the interconversion of pyruvate and
lactate.
The findings above indicated that lactate, as provided through MCT1, can potentially be
used as a fuel by the two epithelial cell breast cancer lines. We therefore examined whether MCT1
function promoted cell growth in epithelial cell lines that display robust MCT1 expression (Figure
3.4. C-D). Treatment of cells with the potent MCT1 inhibitor SR13800, slowed the growth of both
epithelial cell lines, but had no effect on the mesenchymal cells, in the presence of physiological
levels of glucose, lactate, glutamine and pyruvate (Figure 3.5. A-B). In the presence of 0.1 mM,
1 mM or 10 mM lactate but without glucose, glutamine and pyruvate, epithelial cell growth was
moderate, but nevertheless was positively correlated with increasing extracellular lactate, and this
effect of lactate on cell proliferation was blocked by the MCT1 inhibitor (Figure 3.5. C-D).
Increasing extracellular lactate had no effect on mesenchymal cells (Supplemental figure 3.2.).
These data show a differential ability of epithelial breast cancer cells to import lactate for growth.
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Figure 3.5. MCT1 inhibitor treatment reduced the cell proliferation of epithelial MCF-7 and
BT-474 breast cancer cells in normal and nutrient-limited conditions.
Viable cell counts under the following conditions: A-B. Epithelial (E) and mesenchymal (M) cells
were cultured in 3-dimensional Matrigel with 100 mM MCT1 inhibitor SR 13800 for 4 days. CD. Epithelial MCF-7 and BT-474 cell lines were cultured in 3-dimensional Matrigel with
physiological modified medium containing only lactate at 0.1 mM, 1 mM and 10 mM
concentrations for 4 days and treated with or without MCT1 inhibitor SR 13800. Results are
presented as mean ± S.E.M. of three independent experiments; (n=6) *p < 0.05; **p < 0.01; ***p
< 0.001; ****p < 0.0001 (ordinary one-way ANOVA).
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GATA3 Expression Promotes MCT1 Expression
The UCSC Genome Browser shows an H3K27Ac mark coinciding with a DNasehypersensitive region about 5 kb upstream of the human MCT1 transcription start site. Analysis
of this region revealed that it harbors a GATA3 binding site (Figure 3.6. A). The transcription
factor, GATA binding protein 3 (GATA3), is essential for proper mammary development and has
strong association with the expression of the estrogen receptor (ERα) in breast cancer63,64. We
observed that GATA3 knockdown significantly decreased MCT1 and ERα relative expression, but
had no effect on MCT4 (Figure 3.6. B).
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Fig. 6. GATA3 Expression Promotes MCT1 Expression
A. GATA3 binding site in the DNase-hypersensitive region of the human MCT1 gene (UCSC
Genome Browser; ORegAnno Regulatory Site Database65) B. Relative mRNA expression of
transcription factor GATA3, lactate transporters MCT1 and MCT4, and estrogen receptor α (ERα)
in MCF-7-Mock, MCF-7-siNT and MC-7-siGATA3 for 96 hours in MPM culture. Results are
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presented as mean ± S.E.M. of three different experiments (n=6) *p < 0.05; **p < 0.01; ***p <
0.001; ****p < 0.0001 (ordinary one-way ANOVA).
ERα signaling regulates MCT1 expression
The higher expression of MCT1 in ERα-positive epithelial cells raises the possibility that either
ERα directly stimulates MCT1 gene transcription, or that ERα/luminal-related transcription factors
(e.g., GATA3, FOXA166,67) stimulate MCT1 expression. Indeed, treatment of both epithelial
MCF7 and BT474 cell lines with 10 nM E2 or 1

M Tamoxifen in MPM containing some

estrogenic activity (phenol-red, 10% FBS) showed that Tamoxifen significantly suppressed the
expression of MCT1 and progesterone receptor (positive control). MCT4 expression was
unchanged by either E2 or Tamoxifen, demonstrating a selective action on MCT1 expression
(Figure 3.7. A). This raised the possibility that Tamoxifen may suppress breast cancer cell
proliferation, in part, by lowering expression of MCT1, and that the combination adjuvant therapy
with both Tamoxifen and an MCT1 inhibitor may impose a more complete inhibition of growth
and viability in ERα-positive breast cancers. Co-treatment of epithelial MCF-7 and BT-474 cells
with MCT1 inhibitor SR13800 and Tamoxifen inhibited proliferation to a significantly greater
extent than with either drug by itself (Figure 3.7. B) but not mesenchymal breast cancer cells
(Supplemental figure 3.3. C).
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Figure 3.7. ERα signaling regulates MCT1 expression
A. Relative mRNA expression of lactate transporters: MCT1 and MCT4; and progesterone
receptor (PR) of epithelial (E) and mesenchymal (M) breast cancer cells in 3-dimensional Matrigel
culture and treated with 10 nM β-estradiol (E2) or 1 µM Tamoxifen (TAM) for 4 days. B. Viable
cell counts of epithelial MCF-7 and BT-474 breast cancer cells in 3-dimensional Matrigel culture
and treated with 1 µM Tamoxifen (TAM) +/- 100 mM MCT1 inhibitor SR 13800 for 4 days.
Results are presented as mean ± S.E.M. of three different experiments (n=6) *p < 0.05; **p < 0.01;
***p < 0.001; ****p < 0.0001 (ordinary one-way ANOVA).
IV.

Discussion
The behavior and progression of breast cancer is strongly influenced by the tumor

microenvironment, which includes the extracellular matrix and the levels of extracellular nutrients.
The matrix that surrounds cells in a 3-dimensional field impacts the configuration of the cell,
regulates the concentrations of nutrients, exported metabolites and H+ ions, allows cells to
generate motile and stress forces, and modulates intracellular signaling pathways14,68,69.
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Extracellular fuels, specifically glucose, lactate, glutamine and pyruvate, contribute to the levels
of intracellular metabolites, many of which impose allosteric regulation on metabolic pathways
28,70,71

and enable anabolic pathways required for cell proliferation. For example, Elia et al recently

demonstrated that 3D culture of Ras-transformed MCF10A mammary epithelial cells in soft agar
induced a shift towards proline metabolism, and that cells in 3D culture also imported proline,
whereas cell in 2D culture exported proline72.
Therefore, we revisited and extended our previous studies on EMT and metabolic
reprogramming47 by adapting a 3-dimensional culture method in Matrigel, and using a modified
culture medium with 4 major nutrients at approximately physiological concentrations
(“Matrigel/physiological medium” or “MPM”). In MPM culture, the two epithelial and two
derivative mesenchymal cell lines displayed marked morphological differences and
motility/invasiveness that is difficult to perceive in a constrained ‘flat’ plain of the traditional 2dimensional plastic culture. In addition to increased invasiveness within the Matrigel, the two postEMT mesenchymal cell lines displayed a triple-negative phenotype with increased proliferation,
and expressed EMT-related and stem cell-related markers under MPM culture conditions.
Previous studies on metabolic reprogramming in the context of metastatic transformation
or EMT suggest that this process facilitates the metabolic shift toward glycolysis. For example,
the EMT-related transcription factor, SNAIL, mediates the suppression of mitochondrial
respiration through the Wnt/Snail signaling pathway, and enhances glycolysis by silencing the
gluconeogenic enzyme fructose-1,6-bisphosphatase 1 (FBP1) in breast cancer58,73. In a previous
study, we reported that the two mesenchymal cell lines, MCF-7EMT and BT-474EMT underwent an
apparent glycolytic shift, as evidenced by enzyme and transporter expression, glucose uptake,
lactate production and relative sensitivities to several metabolic inhibitors47.
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In the present study, we observed that EMT-induced cancer cells had increased glucose
uptake and lactate production when cultured in 3-dimensional MPM. We also examined in real
time the metabolic changes induced by EMT using the Seahorse extracellular flux technology in
all four cell lines and in physiological modified medium. The significantly lower levels of OCR in
the EMT-induced mesenchymal breast cancer cells were accompanied by an increase in ECAR
levels when compared to the parental epithelial cell lines, confirming a glycolytic shift in the
mesenchymal cell lines.
Acidification of the extracellular fluid (i.e., an enhanced ECAR) is generated primarily by
the co-export of lactate anion and a proton. Lactate is generated from pyruvate, the end product of
glycolysis, by lactate dehydrogenase isoform A (LDHA) -enriched tetramers. This reaction also
oxidizes NADH to NAD+ that is essential for the continuation of a high glycolytic flux. Tetramers
enriched in LDHB catalyze the reverse reaction of lactate to pyruvate. We observed increased
protein levels of both LDHA and LDHB in the two mesenchymal cell lines. LDHA overexpression
is a hallmark of many types of cancer, the majority of which are highly glycolytic, and elevated
levels of LDHA connotes poor prognosis in pancreatic, squamous head and neck, gastric and breast
cancer55,74–76. In contrast, the association of LDHB with breast cancer is more complex. LDHB,
which converts lactate to pyruvate, was shown to be silenced by promoter methylation in breast
cancer cells under hypoxia to enhance glycolysis77. However, one study associated high levels of
LDHB with a more glycolytic and basal-like phenotype among several breast cancer cells

77

.

Moreover, another study showed that LDHB was highly expressed in triple-negative breast cancer
as compared with other subtypes of breast cancer and patients with elevated LDHB experienced
poor clinical outcome
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. Further studies are needed to examine whether the LDH isoforms are

modified in cancer cells in a manner that confers either different enzymatic actions with respect to
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pyruvate and lactate, or entirely new actions that are unrelated to the interconversion of these two
metabolites.
The co-export of lactate and a proton is accomplished by specific isoforms of the
monocarboxylate transporter (MCT) family79. While the release of lactate occurs through the lowaffinity lactate transporter MCT4 (Km≈28 mmol/L), the import of lactate occurs through the highaffinity MCT1 transporter (Km≈1– 3.5 mmol/L). In normal physiology, MCT4 is expressed in
highly glycolytic tissues like type II skeletal muscle fibers and astrocytes and MCT1 is highly
expressed highly oxidative tissues such as cardiac muscle, type I skeletal muscle fibers, and
neurons 26,79. In our study, we observed that both EMT-induced mesenchymal cell lines displayed
increased levels of the MCT4 transporter, and diminished levels of MCT1. The relative expression
of MCT isoforms in relation to different types of breast cancer is not straight forward. Doyen et al
reported that the expression of MCT4 was higher in TNBC compared to normal breast tissues
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and supports the correlation of elevated expression of MCT4 in the triple-negative mesenchymal
cancer cells. In contrast, other studies have demonstrated a strong association of high expression
of MCT1 with triple-negative breast cancer compared to other breast cancer types 81,82. However,
one study reported that only 26% of their 31 TNBC samples showed high expression of MCT1 78.
Interestingly, a recent report showed that MCT1 and MCT4 were co-expressed in some breast
cancer tumors and cell lines 83. One possible explanation for these discrepancies is the plasticity
of tumor cells to adapt to different tumor microenvironments. For example, the relative degree of
vascularization and oxygen saturation in individual samples are typically not reported in studies
of differential gene expression among different breast cancer types.
We observed lower steady state levels of intracellular pyruvate and lactate in the
mesenchymal cells, which, coupled to the findings of elevated glucose uptake, increased LDH and
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MCT4 expression and increased lactate secretion, indicates that glycolytic cells are extremely
efficient at lactate production and removal. Interestingly, lactate secreted by more glycolytic tumor
cells, has been identified as a major energy fuel in tumors. Lactate is taken up by oxygenated tumor
cells which use it to fuel oxidative metabolism27,84. Thus, oxidative tumor cells spare glucose
which may, in turn, reach glycolytic tumor cells. This “lactate shuttle” between tumor cells has
been described in different types of cancer including breast cancer 28.
In contrast to the two EMT-induced mesenchymal cell lines, the two parental epithelial cell
lines displayed a higher OCR but a lower ECAR. Further, the epithelial cells contained
significantly more intracellular pyruvate and lactate. The epithelial cells expressed robust levels
of MCT1 protein but very low levels of MCT4, and readily detectable levels of both LDH isoforms.
These findings indicate that epithelial cells import lactate, convert lactate to pyruvate and maintain
a reservoir of both metabolites to be used to maintain mitochondrial oxidative metabolism. Our
previous study47 and the findings shown in Supplemental Fig 1 indicate that epithelial cells express
enzymes that can redirect carbons in pyruvate through reverse glycolysis and into anabolic and
antioxidant pathways. Thus, MCT1-mediated lactate uptake also likely subserves the ability of
epithelial cells to double their mass for proliferation.
Lactate also functions independently of providing a carbon source, in that elevated levels
of intracellular lactate may also regulate intracellular signaling pathways in epithelial cells 85. For
example, in oxidative cancer cells, lactate has been linked to activation of a “pseudo-hypoxic” Hifassociated signaling, leading to activation of the c-myc signaling pathway, ultimately leading to
an increase in glutamine uptake and metabolism39. Given the complexity of lactate actions, the
MCT1 inhibitor likely decreases the viable cell number for the two epithelial cell lines through
perturbation of multiple pathways. Further studies are needed to examine whether and how the
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higher level of intracellular lactate in the two epithelial cells impacts signaling pathways that
regulate other metabolic pathways, as this information may allow for higher precision in the
inhibition of lactate intake and function to impair cancer cell metabolism (and lead to cell death)
without allowing metabolic adjustments to override the impairments.
Consistent with the fact that MCT1 mRNA and protein expression is significantly higher in ERαpositive epithelial cells, Tamoxifen suppresses MCT1 expression. The combination of Tamoxifen
and an MCT1 inhibitor had an additive effect on the decline in cell number in the two epithelial
cell lines. Also consistent with expression and function of MCT1 in epithelial Luminal A breast
cancer cells, GATA3 also selectively stimulates MCT1 expression. Further studies are needed to
better exploit this interaction of luminal transcription factors, ERα and GATA3, with MCT1 and
lactate metabolism for therapeutic targeting of Luminal A breast cancer cells.
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V.

Supplemental figures

Supplemental figure 3.1. EMT-induced BT-474M and MCF-7M mesenchymal breast cancer
cells showed upregulation of glucose transporters and downregulation gluconeogenic
enzymes.
Real-time qPCR analysis of A. glucose transporters; GLUT1, GLUT3 and GLUT12. B. lactate
transporter; MCT2. C. gluconeogenic enzymes; PCK2, FBP1 and G6PD. Results are presented as
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mean ± S.E.M. of three independent experiments (n>6) *p < 0.05; **p < 0.01; ***p < 0.001; ****p
< 0.0001 (ordinary one-way ANOVA).

Supplemental figure 3.2. Cell proliferation of the EMT-induced mesenchymal MCF-7M and
BT-474M breast cancer cells culture in 3-dimensional Matrigel and nutrient-limited
medium.
A. Mesenchymal MCF-7 M and BT-474 M cell lines were cultured in 3-dimensional Matrigel with
physiological modified medium containing only lactate at 0.1 mM, 1 mM and 10 mM
concentrations for 4 days. Results are presented as mean ± S.E.M. of three different experiments
(n=6) *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001 (ordinary one-way ANOVA).
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Supplemental figure 3.3. Tamoxifen and MCT1 inhibitor treatment does not affect the cell
proliferation of the EMT-induced mesenchymal MCF-7M and BT-474M breast cancer cells.
A. Relative mRNA expression of lactate transporters; MCT2 of epithelial (E) and mesenchymal
(M) breast cancer cells in 3-dimensional Matrigel culture and treated with 10 nM β-estradiol (E2)
or 1 µM Tamoxifen (TAM) for 4 days. B. Viable cell counts of mesenchymal MCF-7M and BT474M breast cancer cells in 3-dimensional Matrigel culture and treated with 1 µM Tamoxifen
(TAM) +/- 100 mM MCT1 inhibitor SR 13800 for 4 days. Results are presented as mean ± S.E.M.
of three different experiments (n=6) *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001 (ordinary
one-way ANOVA).
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CHAPTER 4

GPR81 REGULATES LACTATE METABOLISM IN EPITHELIAL
BREAST CANCER CELLS
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I.

Abstract

G-protein-coupled receptor 81 (GPR81) functions as a receptor for lactate and plays an important
role in cancer progression. However, the expression of GPR81 and its role in the context of
metastatic cancer have not been previously reported. Epithelial-mesenchymal transition (EMT)
promotes metastasis by inducing invasive properties in epithelial tumors. Here, we have studied
the expression of GPR81 in two epithelial breast cancer cell lines (MCF-7 and BT-474) and their
respective EMT-induced mesenchymal progeny (MCF-7 M and BT-474 M). GPR81 was highly
expressed in epithelial breast cancer cell lines and hormone-positive breast cancer tumors but was
suppressed in post-EMT mesenchymal breast cancer cells or triple negative breast cancer (TNBC)
tumors. To determine the role of GPR81 in epithelial breast cancer cells, we silenced the lactate
receptor. GPR81 knockdown resulted in impaired breast cancer cell growth and led to apoptosis.
We found that GPR81 regulated the expression of the lactate importer, monocarboxylate
transporter 1 (MCT1), and the lactate uptake in epithelial breast cancer cells. GPR81 expression
was crucial for breast cancer cell proliferation and survival under nutrient-limited conditions. Our
study indicates that GPR81 might be a potential prognostic marker and therapeutic target in
hormone positive epithelial breast cancer.
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II.

Introduction

Breast cancer is a complex and heterogeneous disease, which includes a range of histologic
subtypes associated with different clinical behavior and patient’s outcomes. Invasive breast cancer
(IBC) is the most predominant form of cancer among women worldwide and the second cause of
cancer-related deaths in women in the United States 5,51. The most common type of IBC is luminal
A, characterized by an adhesive epithelial phenotype and defined by the overexpression of the
estrogen receptor α (ERα) and progesterone receptor (PR). Although Luminal A IBC is a relatively
non-aggressive type and has a good response to endocrine therapy, failure of early detection is
associated with metastatic disease, which in turn is responsible for the majority of deaths in breast
cancer patients.
Metastatic dissemination of IBC starts when cancer cells penetrate the basement membrane
into nearby breast tissue. Invasive breast cancer cells travel to other parts of the body through the
lymphatic system or the circulation, ultimately leading to colonization of distant organs52.
Epithelial-mesenchymal transition (EMT) has been proposed as an early step in the metastatic
process8,52. EMT modifies the adhesion molecules expressed by the cell allowing detachment from
the main tumor mass, and increases motility and invasiveness of previously indolent tumor cells 8.
The process of EMT appears to be induced by exposure of cancer cells to an altered
microenvironment (e.g., hypoxia, increased cytokines), sometimes in conjunction with additional
somatic mutations 10 12.
We previously reported that prolonged mammosphere culture induced EMT in two distinct
epithelial breast cancer cell lines, MCF-7 and BT-474 cells, generated stable populations of
mesenchymal cancer cells, MCF-7M and BT-474M

47,48

. More recently, we showed that EMT

promoted a more glycolytic phenotype compared to the parental epithelial breast cancer cells that
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primarily use oxidative phosphorylation to produce ATP (Chapter 3). The altered metabolic
phenotype induced by EMT involved enhanced aerobic glycolysis along with higher rates of
lactate production.
Several studies have highlighted lactate as a “signaling molecule” that plays a role in cancer
cell migration, angiogenesis, immune escape and metastasis25,37. Elevated levels of lactate within
the tumor microenvironment have been associated with metastasis and poor prognosis of cancer
patients 27,31,34,86–88 Additionally, lactate produced by highly glycolytic cancer cells can be utilized
by neighboring oxidative cancer cells for ATP production, a phenomenon known as “metabolic
symbiosis”27. Specifically, one study showed that human breast cancer tumors exhibited lactate
accumulation ranging from 0.5 mM to 8 mM, which under some circumstances is used as an
alternative energy source by oxidative breast cancer tumor cells28.
Intracellular and extracellular lactate levels are determined, in part, by different isoforms
of the lactate/H+ symporter, termed monocarboxylate transporters (MCTs). These isoforms have
different affinities for lactate and pyruvate, which influence the direction of lactate flux79. MCT1
has a high affinity for lactate and is primarily responsible for lactate influx. Clinical studies for
MCT1 inhibition are being conducted as a potential anti-cancer treatment option for advanced
solid tumors in patients with lymphoma, prostate and gastric89. In contrast, MCT4 has lower
affinity for lactate and is primarily involved in lactate export, which contributes to the acidification
and lactate accumulation in the tumor microenvironment

26,90

. Additional important players in

lactate shuttling between cancer cells are the lactate dehydrogenases A and B (LDHA and LDHB)
that catalyze the reversible conversion of pyruvate to lactate.
Previous studies have identified the cell-surface G-protein-coupled receptor, GPR81, as an
endogenous lactate receptor. The GPR81 family of receptors consists of three highly homologous
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members, GPR109a, GPR109b and GPR81, which are regulated by the specific agonists, 3hydroxybutyrate, 3-hydroxyoctanoate, and lactate, respectively 41. GPR81 has been mainly studied
in adipocytes, in which the receptor is coupled to Gi/q. GPR81 activation by lactate decreases
cAMP production, which ultimately reduces lipolysis 42. Recently GPR81 has been shown to be
upregulated in most cancers (pancreas, colon, liver, breast, cervix) and its expression levels
associated with tumor growth and metastasis

43–46,91

. In this current study, we examined GPR81

expression in the context of metastatic transformation or EMT in breast cancer. We provide
evidence that GPR81 promotes lactate transport in hormone-positive breast cancer cells and its
expression is crucial for their cell proliferation and survival.

III.

Results

Endogenous Lactate Receptor GPR81 Is Highly Expressed In Epithelial Breast Cancer Cells
In 3-Dimensional Culture
As previously described, epithelial (E) MCF-7 and BT-474 cell lines and the corresponding postEMT mesenchymal (M) MCF-7M and BT-474M were cultured in a more physiologically relevant
system using 3-dimensional Matrigel and physiological modified medium (referred as MPM
culture). Under these conditions epithelial breast cancer cells grew as tightly adherent spheroids
for 1 week (Figure 4.1. A; “E” boxes). The two mesenchymal cell lines also formed tight
spheroids initially, but after 2 days began invading the Matrigel (Figure 4.1. A; “M” boxes). After
1 week of MPM culture, cells were examined for the expression of the endogenous lactate receptor
GPR81. Epithelial spheroids expressed relatively high levels of GPR81, whereas mesenchymal
cells showed no or very low expression (Figure 4.1. B).
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Figure 4.1. GPR81 expression of epithelial MCF-7 and BT-474 cells and mesenchymal MCF7M and BT-474M in 3-dimensional Matrigel culture.
A. Fluorescence microscopy images of 3-dimensional structures of proliferating epithelial (E) and
mesenchymal (M) cells in 3-dimensional Matrigel with physiological modified medium for 7 days.
Green, Phalloidin staining of F-actin; Red/orange, nuclei counterstained with SYTOXTM orange
nucleic acid (red). B. Real-time qPCR analysis of GPR81 in epithelial (E) and mesenchymal (M)
cells. Results are presented as mean ± S.E.M. *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001
(ordinary one-way ANOVA).

GPR81 Is Highly Expressed In Human Hormone-Receptor-Positive Breast Cancer Tissues
To determine whether GPR81 was present in human breast cancer tumors, we analyzed
mRNA gene expression profiles from 74 human breast cancer samples and 12 non-tumorigenic
(NT) breast tissues (Supplemental figure 4.1. B). We grouped these samples in non-tumorigenic
(NT), estrogen receptor positive (ER+), amplification of the human epidermal receptor growth
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factor 2 (HER2+) and triple negative breast cancer (TNBC) according to their clinical information
provided by the supplier. Higher levels of GPR81 mRNA were noted in hormone-positive breast
cancer samples (ER+ and HER2+) and significantly lower levels were found in the NT and TNBC
samples (Figure 4.2. A). We also analyzed the relative gene expression of GPR81 by the stage of
human breast cancer. Breast cancer stage II-III had significantly higher GPR81 expression than
stage IV (Figure 4.2. B). Additionally, the Kaplan-Meir survival plot showed that high expression
levels GPR81 was strongly associated with better prognosis and overall survival in breast cancer
patients (Figure 4.2. C) (p-value = 0.0011) (n = 626)92. We also tested GPR81 expression in other
breast cancer cell lines. Hormone-receptor positive HC1500 cells had higher expression of the
lactate receptor compared to the TNBC MDA-MB231 cells (Supplemental figure 4.1. A). These
results demonstrate that GPR81 is mainly expressed in hormone positive and less aggressive types
of human breast cancer.
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Figure 4.2. GPR81 is highly expressed in human hormone-receptor-positive breast cancer
tissues.
A. Relative mRNA expression of GPR81 in NT (n=12) ER+ (n=23), HER2+ (n=14) and TNBC
(n=11) breast cancer tissue. B. Relative mRNA expression of GPR81 in stage I (n=21), II (n=32),
III (n=25) and IV (n=4) of breast cancer. C. Kaplan-Meier plot of estimated overall survival in
breast cancer patients (n=626) with low expression of GPR81, below the median (black line) or
high expression of GPR81, above the median (red line)92. Log-rank test p-value = 0.0011. Results
are presented as mean ± S.E.M. *p < 0.05; **p < 0.01; ***p < 0.001 (two-way ANOVA).
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GPR81 regulates expression of the gene involved in lactate import in MCF-7 epithelial breast
cancer cell line
A previous study reported that GPR81 regulates the expression of lactate transport related
genes MCT1 and MCT4 in pancreatic cancer cells through as yet unknown mechanisms44. To
determine the role of the endogenous lactate receptor GPR81 in the lactate metabolism of ERαpositive breast cancer cells, we silenced GPR81 (~60%) in MCF-7 cancer cells using siRNA
(siGPR81) up to four days in MPM culture (Figure 4.3.A). GPR81 knockdown in MCF-7 cells
led to a 2-fold reduction in mRNA and protein expression of the lactate importer, MCT1, but had
no significant effect on the lactate exporter, MCT4 (Figure 4.3. B-C). In addition, GPR81 did not
significantly alter the expression of other lactate metabolism-related genes (LDHA, LDHB,
MCT2) (Supplemental Figure 4.2.).
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Figure 4.3. GPR81 regulates expression of the gene involved in lactate import in MCF-7
epithelial breast cancer cell line.
A. Real-time qPCR analysis of GPR81, B. MCT1 and MCT4 mRNA levels in MCF-7-siNT
(control) and MCF-7-siGPR81 cultured in 3-dimensional Matrigel with physiological modified
medium at 72 and 96 hours after transfection. C. Western blot analysis of cell lysates from MCF7-siNT and MCF-7-siGPR81 cells used to detect protein expression levels of MCT1 and MCT4.
β-actin was used as a loading control. The bars represent the mean ± S.E.M of three independent
experiments; *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001 (ordinary one-way ANOVA).

GPR81 regulates lactate uptake in MCF-7 epithelial breast cancer cell line
We previously reported that the two epithelial breast cancer cell lines had higher steady
state levels of intracellular lactate and pyruvate than the corresponding post-EMT mesenchymal
cell lines (see Chapter 3). Given that MCT1 is primarily a lactate importer, we hypothesized that
the reduction of MCT1 expression may affect the lactate uptake of the epithelial MCF-7 breast
cancer cells. To test this hypothesis, we measured the intracellular lactate of non-targeted control
MCF-7-siNT and MCF-7-siGPR81 in MPM culture using NMR analysis. MCF-7-siGPR81 cells
had significantly lower intracellular lactate compared to MCF-7-siNT cells (Figure 4.4. A),
indicating reduced lactate uptake of MCF-7-siGPR81 cells. Additionally, GPR81 knockdown
resulted in higher levels of lactate in the culture medium but not control MCF-7-siNT cells (Figure
4.4. B). We did not detect a significant change in glucose consumption (Figure 4.4. C). Taken
together, these data suggest a role for GPR81 in the regulation of the lactate uptake of the epithelial
MCF-7 breast cancer cells.
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Figure 4.4. GPR81 regulates lactate uptake in MCF-7 epithelial breast cancer cell lines.
Intracellular lactate of MCF-7-siNT (control) and MCF-7-siGPR81 measured using NMR analysis
after 72 hours of transfection. B. Lactate concentration in the medium of MCF-7-siNT 10 nM and
MCF-7-siGPR81 10 nM were measured after 96 hours of transfection. C. Glucose consumption
rate of MCF-7-siNT and MCF-7-siGPR81 were measured after 96 hours of transfection. MCF-7siNT and MCF-7-siGPR81 cells were cultured and transfected in 3-dimensional Matrigel with
physiological modified medium and measurements were taken after 24 hours of culture in fresh
medium. The bars represent the mean ± S.E.M of three independent experiments; *p < 0.05; **p
< 0.01; (ordinary one-way ANOVA).
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GPR81 is required for cancer cell proliferation and cancer cell survival when lactate is the
primary fuel source.
Lactate has been previously suggested as an alternative energy source for aerobic breast
cancer cells27,28,93. To determine whether GPR81 plays a role in breast cancer cell proliferation,
we studied the increase in viable cell numbers and the expression of cell proliferation markers
(taken from the OncotypeDx recurrence score assay) in control MCF-7-siNT and MCF-7-siGPR81
cells. Silencing of GPR81 led to about 40% reduction in cell proliferation of MCF-7-siGPR81
(Figure 4.5.A) and decreased relative gene expression of proliferation markers; Ki67, Cyclin B1,
PCNA and STK15 (Figure 4.5. B). Furthermore, the expression of the cell apoptosis marker,
cleaved PARP, was significantly increased by 2-fold in MCF-7-siGPR81 cells when compared to
control MCF-7-siNT cells (Figure 4.5. C).
In order to determine whether GPR81 expression is required for cell growth and survival,
we cultured control MCF-siNT and MCF-7-siGPR81 cells in 3-dimensional Matrigel with
physiological medium lacking glucose, glutamine and pyruvate and with 0.1 mM, 1 mM or 10 mM
lactate as the main available nutrient source. Despite the significant increase in cell number of the
MCF-7-siNT cells when cultured in medium containing only 1 mM and 10 mM lactate, GPR81
silencing prevented cell growth under these nutrient-limited conditions. Similarly, we found that
treatment with the MCT1 inhibitor also prevented cell growth when in MCF-7 cells were culture
in nutrient-limited conditions. Taken together, these data support the physiological role for GPR81
in the regulation of lactate uptake, cell proliferation and survival of the epithelial MCF-7 breast
cancer cells under nutrient-limited conditions.
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Figure 4.5. GPR81 is required for cancer cell proliferation and cancer cell survival when
lactate is the primary fuel source.
A. Viable cell counts of MCF-7-siNT (control) and MCF-7-siGPR81 after 72 and 96 hours of
transfection and subtracting the initial cell number. B. Real-time qPCR analysis of proliferation
markers: Ki67, Cyclin B1, PCNA and STK15. C. Western blot analysis of cell lysates from MCF7-siNT and MCF-7-siGPR81 cells after 72 and 96 hours of transfection used to detect protein
expression levels of the apoptotic maker cleaved-PARP. β-actin was used as a loading control. D.
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MCF-7-siNT and MCF-7-siGPR81 breast cancer cells were cultured in 3-dimensional Matrigel
with physiological modified medium containing only lactate at 0.1 mM, 1 mM and 10 mM
concentration for 96 hours. E. MCF-7 breast cancer cells were cultured in 3-dimensional Matrigel
with physiological modified medium containing only lactate at 0.1 mM, 1 mM and 10 mM
concentration and treated with or without MCT1 inhibitor SR 13800 for 96 hours. Viable cell
counts after treatment. Results are presented as mean ± S.E.M. of three independent experiments;
*p < 0.05; **p < 0.01; ***p < 0.001 (ordinary one-way ANOVA).

Additive effect of GPR81 knockdown and Tamoxifen treatment in reducing the cell
proliferation and increasing cell apoptosis in epithelial MCF-7 breast cancer cells.
Previously, we showed that 1 µM Tamoxifen significantly reduced the expression of
MCT1 in epithelial breast cancer cell lines (Chapter 3). We observed here that Tamoxifen further
reduced MCT1 gene expression in GPR81-silenced MCF-7 cells treated for 4 days (Figure 4.6.A).
We next evaluated the effects of Tamoxifen and GPR81 silencing on cell proliferation and
apoptosis in ER+ MCF-7 breast cancer cells. GPR81 knockdown and Tamoxifen treatment had an
additive effect on the reduction of cell proliferation markers; Ki67 and Cyclin B1 (Figure 4.6.B),
as well as viable cell numbers of MCF-7 cells in MPM culture (Figure 4.6. C). Additionally, cell
apoptosis was significantly increased only in MCF-7-siGPR81 cells independently of Tamoxifen
treatment, showed by the increased expression of the apoptotic marker cleaved PARP. These data
suggest GPR81 regulates cell proliferation and apoptosis.
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Figure 4.6. Additive effect of GPR81 knockdown and Tamoxifen treatment in reducing the
cell proliferation and increasing cell apoptosis in epithelial MCF-7 breast cancer cells.
MCF-7-siNT (control) and MCF-7-siGPR81 cancer cells were treated with or without 1µM
Tamoxifen for 96 hours in 3-dimensional Matrigel with physiological modified medium. A. Realtime qPCR analysis of lactate importer MCT1; and progesterone receptor PR. B. Relative mRNA
expression of proliferation markers: Ki67 and Cyclin B1. C. Viable cell counts of epithelial MCF7-siNT and MCF-7-siGPR81. D. Western blot analysis of cell lysates from MCF-7-siNT and
MCF-7-siGPR81 used to detect protein expression levels of the apoptotic maker cleaved-PARP.
β-actin was used as a loading control. Results are presented as mean ± S.E.M. of three independent
experiments *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001 (ordinary one-way ANOVA).
IV.

Discussion
The metabolic changes that cancer cells undergo in order to support macromolecule

biosynthesis, growth and survival, are collectively referred to as “metabolic reprogramming”, now
considered a hallmark of cancer cell biology14,54. Although there is increasing attention on cancer
metabolic reprogramming, most studies have been performed in the setting of neoplastic
transformation and less is known how metabolic reprogramming contributes to metastatic
transformation. For example, it has been shown that the EMT-transcription factor SNAIL mediates
the suppression of mitochondrial respiration and enhances glycolysis in breast cancer58,73. More
recently, we demonstrated that EMT induced a metabolic shift to a less oxidative and more
glycolytic metabolism in two epithelial cell lines, MCF-7 and BT-474, as evidenced by increased
glucose uptake and lactate production along with increased expression of enzymes and
transporters47 (Chapter 3). These studies suggest that metastatic transformation or EMT facilitates
the metabolic switch toward glycolysis.
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Metabolic reprogramming induced by EMT was associated with a striking switch in the
expression of the lactate transporters MCT1 and MCT4. Epithelial breast cancer cells express high
levels of the lactate importer MCT1 and import lactate as an alternative energy source. In contrast,
the mesenchymal cells showed a marked decreased expression of MCT1 and upregulation of the
lactate exporter MCT4. This MCT4 upregulation was previously reported in triple negative breast
cancer and high levels of this lactate exporter were associated with poor prognosis and survival80,94.
As a result of the glycolytic shift induced by EMT, mesenchymal cells secrete higher amounts of
lactate acid to the extracellular microenvironment which creates an acidic microenvironment that
has been associated with tumor progression19. In addition, previous studies determined that
extracellular lactate plays a critical role in cancer progression and metastasis by promoting cancer
cell migration, immune escape and angiogenesis 31–33,35. Most recently, lactate has been shown to
act as a “signaling molecule”, which, once imported by the cancer cell regulates intracellular
signaling pathways like HIF1α-associated signaling39, or binding directly to the metastatic
activator NDRG3 (N-Myc Downstream Regulated Gene 3) 40. In both cases a signaling cascade
was triggered to promote tumor angiogenesis and tumor growth in vivo.
Lactate has been identified as the ligand for the endogenous cell-surface G-protein-coupled
receptor 81 (GPR81). This lactate receptor was first discovered and mostly studied in adipocytes,
in which lactate activates GPR81 to decrease the cAMP production to ultimately reduce lipolysis42.
GPR81 is highly expressed in neurons95, and when activated, it is able to modify electrical activity
of primary neuronal cells96. Also, the activation of GPR81 by lactate has been identified as the
initial step for an anti-inflammatory response in pancreas, liver and uterus97–99.
More recently, GPR81 expression has been found to be upregulated in several types of
cancer, including pancreatic, colon, liver, breast, lung and cervical cancers, and in several cases
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high GPR81 expression was associated with tumor growth, chemoresistance and metastasis43–46.
Our study provides the first examination of GPR81 expression in the context of metastatic
dissemination or EMT. We showed that hormone-positive epithelial breast cancer cells highly
expressed GPR81, but after EMT induction and transformation into triple negative mesenchymal
cancer cells, the expression of this lactate receptor was significantly reduced. Lee et al reported
that GPR81 expression is significantly increased in breast cancer patients compared to normal
mammary tissues43. We also observed a significant association between GPR81 overexpression
with estrogen receptor (ERα)-positive and human epidermal growth human epidermal growth
factor-2 receptor (HER2) positive human breast cancer tissues as opposed to triple negative breast
cancer. This is consistent with previous observations that ERα-positive breast cancer tissues
overexpressed GPR8143. In addition, GPR81 was expressed at higher levels in the first three stages
of breast cancer (Stage I, II and III) as compared to Stage IV, and GPR81 expression correlated
with better overall survival of breast cancer patients. These findings suggest that GPR81 may be
an important regulator in hormone-positive breast cancer and could be used as a prognostic marker
in the progression of breast cancer.
GPR81 was reported to regulate the expression of genes involved in lactate metabolism,
including lactate transporters, MCT1 and MCT4, in pancreatic cancer cells44. In partial agreement,
our study revealed that GPR81 specifically regulates the lactate importer MCT1, but not lactate
exporter MCT4, in epithelial breast cancer cells. Oxidative breast tumor cells with high expression
of the lactate importer, MCT1, have been reported to import and oxidize extracellular lactate, a
mechanism that is essential for cell viability under glucose deprivation28,93,100. In fact, Park et al
showed that epithelial breast cancer cells imported and utilized

14

C-lactate for mitochondrial

respiration 43. We previously showed that inhibition of the lactate importer, MCT1, reduced cell
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proliferation in epithelial but not mesenchymal cancer cells when lactate was used as the primary
metabolic substrate. Here we report that GPR81 silencing caused downregulation of MCT1 as well
as reduced cell growth in epithelial breast cancer cells when grown in complete MPM medium.
We previously reported that the two epithelial breast cancer cell lines contained significantly
higher intracellular lactate and pyruvate than the two corresponding post-EMT mesenchymal cell
lines. In the present study, we observed that GPR81-silenced cells had lower intracellular lactate
and higher levels of lactate in MPM culture media compare to control cells, indicating reduction
in lactate uptake. Furthermore, we found a protective effect of GPR81 against apoptosis, which
was previously described in epithelial MCF-7 breast cancer cells, where GPR81 activation
triggered the PI3K/Akt signaling pathway to inhibit apoptosis43. Together these results suggest a
specific regulation of GPR81 on lactate importer MCT1, which affects cell proliferation, apoptosis
and survival of hormone-positive epithelial breast cancer cells.
In adipocytes, GPR81 is coupled to Gi/q which inhibits adenylate cyclase activity and
decreases the production of cAMP. However, a previous study did not find a significant change
in cAMP levels when GPR81 was silenced in epithelial MCF-7 breast cancer cells43, suggesting
that GPR81 regulates MCT1 expression by another signaling pathway in these cells. It should also
be noted that previous studies indicate that lactate activates GPR81 in the millimolar range (1 to 5
mM), and in human breast cancer tissues lactate was found to be at concentrations as high as 8
mM28, suggesting that GPR81 and downstream signaling pathways could be constantly activated
by lactate in the breast tumor microenvironment . Further studies are needed to examine which
signaling pathways are linked to GPR81 in epithelial breast cancer, as these pathways may provide
targets for future development of adjuvant therapies for Luminal A breast cancer.
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V.

Supplemental figures
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Supplemental figure 4.1. GPR81 expression in breast cancer cell lines and tissue samples.
A. Real-time qPCR analysis of lactate receptor GPR81; lactate transporters: MCT1, MCT2 and
MCT4 and hormone/growth factor receptors: ER, PR and HER2 in HC1500 and MDA-MB 231
breast cancer cell lines B. Relative mRNA expression of lactate receptor GPR81 in breast cancer
tissue samples (n=74) and non-tumorigenic breast tissue (n=12). Results are presented as mean ±
S.E.M. of three independent experiments *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001
(ordinary one-way ANOVA).
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Supplemental figure 4.2. GPR81 knockdown effect on relative mRNA expression of A.
GPR81 homologous genes: GPR109A and GPR109B; B. lactate transporter MCT2; lactate
dehydrogenases: LDHA and LDHB; glucose transporters: GLUT1, GLUT3 and GLUT12; and
gluconeogenic enzymes: PCK2, FBP1 and G6PD in MCF-7-siNT (control) and MCF-7-siGPR81
cultured in 3-dimensional Matrigel with physiological modified medium at 72 and 96 hours after
transfection. Results are presented as mean ± S.E.M. of three independent experiments *p < 0.05;
**p < 0.01; ***p < 0.001; ****p < 0.0001 (ordinary one-way ANOVA).

72

CHAPTER 5

SUMMARY AND FUTURE DIRECTIONS
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I.

Summary
Epithelial-mesenchymal transition (EMT) induces invasive properties in epithelial tumor

cells and promotes metastasis. Previously, we induced EMT in two distinct epithelial breast cancer
cell lines, MCF-7 and BT-474 cells that generated stable populations of mesenchymal cancer cells,
termed MCF-7M and BT-474M cells, respectively47,48. A previous characterization of these cell
lines using standard 2-dimensional culture on plastic dishes and a standard tissue culture medium,
revealed that both epithelial MCF-7 and BT-474 cells are less glycolytic than the two
mesenchymal MCF-7M and BT-474M cell lines47. In chapter 3 we examined the degree of
oxidative vs glycolytic metabolism in these 4 cell lines, using a more physiological culture system
that involves both a 3-dimensional Matrigel matrix and media containing the physiological levels
of glucose, lactate, glutamine and pyruvate, termed MPM culture. Under these MPM culture
conditions, both epithelial and mesenchymal cell lines maintained their phenotypic features and
they showed marked morphological and behavioral differences. We further studied the metabolic
shift induced by EMT using the Seahorse extracellular flux technology. We found that
mesenchymal cancer cells had significant lower levels of oxygen consumption rate (OCR) and
increased levels of extracellular acidification (ECAR) when compared to the parental epithelial
cell lines, confirming a glycolytic shift induced by EMT. We further examined the metabolic
differences in lactate flux and utilization by these four cell lines. We found that EMT induced
overexpression of the lactate dehydrogenases LDHA and LDHB. In addition, EMT-induced
mesenchymal cells downregulated the expression of the lactate importer MCT1 and overexpressed
the lactate exporter MCT4. We also found that intracellular lactate and pyruvate were significantly
lower in EMT-induced mesenchymal cancer cells. Together, these changes in lactate metabolism
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induced by EMT support the glycolytic metabolism of mesenchymal cancer cells. In contrast, we
found that oxidative epithelial cancer cells that highly expressed MCT1 are able to import lactate
and use it as a nutrient source to support cell growth. Furthermore, we discovered that the
transcription factor GATA3 and ERα signaling regulate the expression of the lactate importer
MCT1, and the treatment with both Tamoxifen and MCT1 inhibitor has an additive effect on
reducing cell growth of epithelial cancer cells.
In Chapter 4, we further continued our studies on lactate metabolism by examining the
expression and role of the endogenous lactate receptor GPR81 in the context of EMT. We found
that GPR81 is highly expressed in epithelial cancer cell lines but not in the derived EMT-induced
mesenchymal cancer cell lines. Also, GPR81 overexpression was significantly associated with
hormone-positive breast cancers and better overall survival of breast cancer patients. These
findings suggest that GPR81 may be an important regulator in hormone-positive breast cancer and
could be used as a prognostic marker in the progression of breast cancer. We observed that
silencing of GPR81 downregulates the expression of the lactate importer MCT1, but not lactate
exporter MCT4. In addition, GPR81 silencing caused decreased intracellular lactate, reduced cell
proliferation and increased apoptosis in the epithelial cancer cells. Also, GPR81 expression was
crucial for cell growth and survival of the epithelial cancer cells, when lactate was the only nutrient
source available in the culture media. Together these findings suggest that GPR81 regulates lactate
import through MCT1 expression by a mechanism yet to be elucidated. Furthermore, we found
that Tamoxifen treatment and GPR81 silencing have an additive effect on reducing MCT1
expression and cell proliferation in epithelial breast cancer cells.
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II.

Future Directions
i.

Lactate metabolism

We found that epithelial breast cancer cells exhibited an oxidative metabolism while the
EMT-induced mesenchymal cancer cells have an enhanced glycolytic metabolism. To gain better
insight into how both epithelial and mesenchymal cells metabolize glucose, we propose to perform
glucose flux studies using 13C-glucose and NMR. We will be able to determine the rates of glucose
uptake, track the amount of glycolytic-derived lactate and other metabolites. We hypothesize that
the rates of glucose uptake and glycolysis will be increased in the EMT-induced mesenchymal
cancer cells.
We also found that epithelial breast cancer cells express high levels of the lactate importer
MCT1 and the blockage of this lactate importer with MCT1 inhibitor reduced significantly their
cell growth when lactate was only nutrient available. To confirm the ability of epithelial cancer
cells to import lactate across the plasma membrane and use it to fuel their oxidative
phosphorylation, we propose to perform lactate flux studies using

13

C-lactate and NMR. We

propose to examine lactate uptake rates and lactate-derived metabolites by culturing the cells in
glucose-deprived medium with

13

C-lactate and analysis of intracellular

13

C-lactate and

13

C-

pyruvate by NMR. Also, we could use this approach to study how the blocking the lactate import,
using treatments with MCT1 inhibitor or Tamoxifen or silencing of GATA3, affect the
intracellular 13C-lactate in epithelial breast cancer cells.
ii.

Lactate transporters

We found high levels of lactate importer MCT1 in epithelial cancer cells, whereas EMTinduced mesenchymal cancer cells expressed high levels of lactate exporter MCT4, in either case
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itis necessary to know whether MCT1 and MCT4 are functional transporters properly localized at
the plasma membrane. We propose to examine the localization of these lactate transporters in
epithelial and mesenchymal cancer cells using confocal microscopy and specific antibodies for
MCT1 and MCT4.
Also, we found that the transcription factor GATA3 regulates the expression of the lactate
importer MCT1 but not lactate exporter MCT4. We propose to confirm this interaction and
regulation using a luciferase gene reporter assay with a vector containing the sequence for GATA3
binding site of the MCT1 promoter (with or without mutation) followed by the luciferase reporter
gene. This approach will allow us to verify the transcriptional regulation of GATA3 on the gene
expression of the lactate importer MCT1.
EMT induced the overexpression of the lactate exporter MCT4 in mesenchymal cancer
cells. We propose to examine the effects of blocking MCT4 in EMT-induced mesenchymal cells
using specific MCT4 inhibitors. In addition, we propose to study MCT4 regulation in EMTinduced mesenchymal cells using a signaling pathway panel of inhibitors containing 12 to 16
inhibitors to elucidate a specific signaling cascade.
Finally, it will be important to examine the effects of both knockdown and overexpression
of MCT1 and MCT4, along with inhibitors of MCT1 and MCT4, on cell proliferation, growth and
possibly metabolic adaptations in the context of orthologous transplantation of cells into the
mammary fat pads of immunodeficient mice.
iii.

Lactate receptor GPR81

We propose to study the localization of the lactate receptor GPR81 in epithelial and
mesenchymal breast cancer cells by transfecting them with the plasmid pCMV6-AC-GFP
(Origene), which contains the GPR81 ORF sequence tagged with GFP at the C-terminal region
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(GPR81-GFP). Our preliminary studies using these plasmids indicate that GPR81 localizes at the
plasma membrane in epithelial breast cancer cells but GPR81 is restricted to the nucleus in EMTinduced breast cancer cells. Further studies are needed to confirm the localization of GPR81 in
these specific compartments in the cell using control proteins at the plasma membrane or nucleus.
We found a significant association between hormone-positive breast cancer tissues and
cells with overexpression of GPR81. Further studies would examine whether epithelial breast
cancer-related transcription factors (e.g., ERα, GATA3, FOXA1) stimulate GPR81 gene
transcription.
Previous studies on normal cells (e.g., adipocytes) revealed that the lactate receptor GPR81
blocks adenyl cyclase to lower the levels of cAMP and increase intracellular Ca+2 levels. Although,
previous studies showed no change in cAMP levels when GPR81 was silenced epithelial cancer
cells43, we propose to attempt to reproduce this finding in epithelial cancer cells culture in MPM.
If we also observe no changes in cAMP levels in response to GPR81 knockdown or
overexpression, we propose to use pharmacological and siRNA screens to identify the signaling
pathway(s) that is/are coupled to GPR81.
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APPENDIX
Appendix: Primer sets for real-time qPCR

GENE
SYMBOL
TBP
ZEB1
ZEB2
CDH1
GATA3
VIM
CD24
CD44
GPR81
GPR109A
GPR109B
ERα
PR
HER2
Cyclin B1
KI67
PCNA
STK15
MCT1
MCT2
MCT4
LDHA
LDHB
PCK2
FBP1
G6PD
GLUT1
GLUT3
GLUT12

FORWARD PRIMER

REVERSE PRIMER

TTGCTGCGGTAATCATGAGG
TGCACAAGAAGAGCCACAAG
ATGCTTTTGCCCAACTGCTG
TTGAACGAATGGGGCAATCG
ATGAAGCCTAAACGCGATGG
TCTCAGCATCACGATGACCTTG
AACTAATGCCACCACCAAGG
AAGGTGGAGCAAACACAACC
TCATTGTGGCCTTTGTGCTG
AAGATCTCCAATCGGACAGCAG
TGGTGCTCTTCATGTTTGCC
TTGAAACACAAGCGCCAGAG
TGCAGACTTTACAGGCAAGC
TTTTGGGGCCAAACCTTACG
AAGGCGAAGATCAACATGGC
TGCAGCAAAACAGCCATCTG
AACCTGCAGAGCATGGACTC
AATTCTTCCCAGCGCATTCC
TGGTGACCATTGTGGAATGC
AGCAGAAATGCCACCAATGC
TTCGGCTGTTTCGTCATCAC
CATGGCAGCCTTTTCCTTAG
AACATGGCGACTCAAGTGTG
TGCGTATTATGACCCGACTG
AAGTCATCCTTTGCCACGTG
TGCCCGAAAACACCTTCATC
ATGCCGATTTGGTTCCTGTG
TTGACGGACAAGGGAAATGC
AAAGCAATGAGGCAGCTAGC

TTTTCTTGCTGCCAGTCTGG
TGCGCAAGACAAGTTCAAGG
ACAGAGAGGGCAGGAAAAGTTC
ACCAGCAACGTGATTTCTGC
TGAGCTCCTTTGCAAAGTGG
TTGCGCTCCTGAAAAACTGC
ATGCAGAAGAGAGAGTGAGACC
TCGACTGTTGACTGCAATGC
AATCAGCCACGGCCAAATTG
AATTTGCACCGCCATTCTGG
TGATGGCTGCTGTCCAATTG
TTTGATCATGAGCGGGCTTG
AGGGCAAAGAGGACAAATGC
ACATCAATGGTGCAGATGGG
TTTGGCCTGCAGTTGTTCAC
TTCCTGGGCGTTTTTGCTAC
TCATTGCCGGCGCATTTTAG
TGGTTGCCTGCAATTGCTTC
AATTAGGACGACGCCACATG
AAGCTGCTCCAACCACAATC
TCCCAAACTCCTGTATGAGCTC
ATGACCAGCTTGGAGTTTGC
AGGCACTTTCAACCACCATC
TCAGGGTTTTCTCTGGGTTG
TTTACCCCTTTTCTCCGGTTCC
TCACTCTGTTTGCGGATGTC
TTTTCTGAGTGCCTGCTGTG
TTGAATTGCGCCTGCCAAAG
ATGTTTTGCTGCCGACATGG
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